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Abstract 
 
Chronic kidney disease (CKD) is a substantial global health burden that has recently been 
linked to the genetic locus SHROOM3 by several genome-wide association studies. Shroom3 
is an actin-binding protein that is necessary for inducing apical constriction in epithelial cells. 
Our lab has previously shown that Shroom3 is critical for proper kidney development and 
loss of Shroom3 produces symptoms associated with CKD. As hypertension is both a leading 
cause and comorbidity of CKD, I hypothesized that loss of Shroom3 confers increased 
susceptibility to hypertension. Using a high-salt induced model of hypertension, I show that 
Shroom3 deficient mice do not become hypertensive but exhibit an increased salt-sensitive 
blood pressure response. Additionally, I show that human SHROOM3 variants currently 
identified within our population have attenuated apical constriction activity. Collectively, the 
findings from our in vivo and in vitro work implicate the consequences of reduced Shroom3 
function in the pathophysiology of human disease.   
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Chapter 1  
1 Introduction 
Studying the contribution of genetic factors to the pathogenesis of human diseases has 
been invaluable in advancing our fundamental understanding of disease susceptibility and 
processes. These studies can begin at the level of genome-wide association studies 
(GWAS) that specifically aim to identify novel genetic risk factors by detecting 
associations between genetic variants within the human population and complex disease 
traits. The work presented in my thesis focuses on one such candidate gene, SHROOM3 
that has been identified by several GWAS as having a strong correlation to chronic 
kidney disease (CKD). Shroom3 is an actin-binding protein that has been characterized as 
a regulator of epithelial cell shape change during morphogenesis. Although it is most 
widely recognized for its role during development, increasing evidence for a role of 
Shroom3 in a range of human disorders is emerging, many of which have developmental 
origins. Recently, direct functional support for the GWAS that have strongly associated 
SHROOM3 to CKD has been provided using several animal models (Khalili et al., 2016; 
Yeo et al., 2015). These studies have shown that Shroom3 is critical for proper kidney 
function and loss of Shroom3 produces phenotypes associated with CKD symptoms. 
However, whether decreased Shroom3 activity directly increases susceptibility to disease 
remains unknown. The aim of my project is to investigate how altered Shroom3 activity 
has the potential to predispose individuals to disease by answering two research 
questions: does Shroom3 deficiency increase susceptibility to hypertension and do 
potentially damaging SHROOM3 variants currently identified within the human 
population have compromised cellular function?  
1.1 The Mammalian Kidney 
1.1.1 Functional Anatomy  
The kidneys are bilateral organs of the renal system that fulfill a number of vital 
functions, of which the most fundamental is the filtration of blood. Specifically, the 
kidneys remove excess waste and toxic metabolic compounds then excrete them into 
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urine, while simultaneously reabsorbing nutrients and water (Davidson, 2008; Takasato 
& Little, 2015; Tanner, 2009). In addition to overseeing this essential physiological 
process, the kidneys are also important regulators of homeostasis as they help maintain 
blood pressure and bone density as well as water, pH, electrolyte, and acid-base balance 
(Little & McMahon, 2012; Tanner, 2009).  
Each kidney can be separated into two distinct regions: a peripheral layer, the cortex, and 
an inner layer, the medulla (Tanner, 2009). The medulla is further subdivided into an 
inner medulla and outer medulla, which contains the collecting ducts and short loops of 
Henle (Davidson, 2008). The cortex comprises all other nephron components including 
the glomeruli, convoluted tubes, and cortical collecting ducts, and is where primary 
filtration takes place (Tanner, 2009). This gross anatomical division establishes an 
osmotic gradient between the cortex and medulla that is critical for the absorption of 
water from urine (Davidson, 2008).  
1.1.2 Renal Physiology  
Filtration in the kidney takes place in functionally independent units known as nephrons, 
that are found throughout the cortex and medulla (Figure 1.1) (Davidson, 2008). 
Typically, there are around one million nephrons present in a human kidney and around 
11 000 in a mouse kidney (Davidson, 2008). Each nephron consists of the glomerulus, 
Bowman’s capsule, and a double hairpin-shaped tubule that drains into the renal pelvis 
(Kurts et al., 2013). Three processes occur within the nephron in order to form urine: 
glomerular filtration, tubular reabsorption, and tubular secretion (Tanner, 2009).  
First, blood is supplied to the kidney by the renal artery. The incoming vascular network 
is then subdivided until a single afferent arteriole enters the glomerulus where it is 
subdivided into a capillary network and exits via a single efferent arteriole (Schwartz & 
Furth, 2007; Tryggvason, 2005). The capillaries are surrounded by the foot processes of 
epithelial podocytes that filter the blood as part of the glomerular filtration barrier (GFB) 
(Brinkkoetter et al., 2013). The plasma filtrate is pooled into the urinary space of the 
Bowman’s capsule and travels down the proximal convoluted tubule, where the majority  
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Figure 1.1 Structure of the mammalian kidney. A schematic diagram showing the 
gross anatomical structure of the kidney sectioned longitudinally (left) and a close-up of 
the renal lobe showing the orientation of the nephron relative to the kidney (right). 
Adapted from Pearson Education (2009). 
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of water reabsorption takes place through the peritubular capillaries (Lote, 2013; Tanner, 
2009). Simultaneously, organic ions including drugs and toxins from the blood are 
secreted into the filtrate (Lote, 2013; Tanner, 2009). Further reabsorption of water and 
some solutes is carried out by the peritubular capillaries as the filtrate travels through the 
loops of Henle towards the distal convoluted tubule (Lote, 2013; Tanner, 2009). While 
passing through the distal convoluted tubule, metabolic waste products (i.e. hydrogen and 
potassium ions) found in the blood are secreted into the filtrate (Lote, 2013; Tanner, 
2009). Lastly, the filtrate reaches the collecting duct where the final reabsorption of water 
takes place, concentrating the urine before it is projected into the ureter for excretion 
(Lote, 2013; Tanner, 2009). 
1.1.2.1 Nephrogenesis  
Mammalian nephrogenesis occurs through three morphological stages known as the 
pronephros, mesonephros, and metanephros. The final and only non-transitory stage, the 
metanephros, gives rise to the definitive adult kidney (Davidson, 2008). Kidney 
development is initiated and maintained through the reciprocal interactions between two 
key embryonic tissues derived from the intermediate mesoderm: the ureteric bud (UB) 
and the metanephric mesenchyme (MM) (Takasato & Little, 2015). At E10.5-11 in mice, 
the MM induces the formation of the UB as an outgrowth of the pronephric duct. The UB 
then invades the MM, marking the initiation of metanephric development (Davidson, 
2008). Upon invasion of MM, the UB undergoes a process of branching morphogenesis 
through sequential rounds of division to elongate into a ureteric tee, which ultimately 
gives rise to the collecting duct system (Short & Smyth, 2016). Simultaneously, induction 
of the MM by the UB causes a subpopulation of condensed MM near the UB tips to 
cluster into pre-tubular aggregates that eventually differentiate into nephrons (Short & 
Smyth, 2016). Nephron differentiation involves the dynamic process of mesenchymal-to-
epithelial transition that facilitates the morphogenesis of the pre-tubular aggregate into a 
renal vesicle, a comma-shaped body, and an s-shaped body (Dressler, 2006). Once the s-
shaped body is formed, the proximal end becomes invaded by blood vessels marking the 
initiation of glomerulogenesis while the distal end fuses with the collecting duct 
(Dressler, 2006). This highly conserved process of nephron formation occurs during the 
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later stages of organogenesis; in mice, nephron formation continues until 14 days after 
birth, while in humans, it ceases at 36 weeks of gestation (Davidson, 2008; Short & 
Smyth, 2016). 
1.1.2.2 Glomerular Filtration 
The glomerulus is a specialized structure comprised of a capillary network underlying the 
Bowman’s capsule that functions to ultrafiltrate plasma (Figure 1.2) (Lote, 2013). The 
glomerular filter, or glomerular filtration barrier (GFB), serves as a macromolecular sieve 
restricting the passage of large plasma proteins (i.e. albumin) while simultaneously 
allowing the passage of plasma water and small solutes (Kasner et al., 2013). 
Perturbations to the GFB and its constituent layers have been shown to result in the 
leakage of protein into urine, a marker of CKD (Menon et al., 2015). There are three 
layers comprising the GFB: the fenestrated endothelial cells, the glomerular basement 
membrane (GBM), and the epithelial podocyte cells (Haraldsson et al., 2008). 
Importantly, the critical role of podocytes in maintaining the structural integrity of the 
GFB has been evidenced by multiple studies, one of which found that all single gene 
mutations causing nephrotic disorders reside in podocyte-specific genes (Wiggins, 2007). 
1.2 Chronic Kidney Disease 
1.2.1 Epidemiology   
Chronic kidney disease (CKD) is a major public health concern, currently affecting 11-
13% of the global population and increasing in prevalence (Hill et al., 2016). CKD is a 
condition defined by a progressive decline in renal function as indicated by the presence 
of structural or functional abnormalities in the kidney sustained for longer than 3 months 
(Moe et al., 2017; National Kidney Foundation, 2002; Webster et al., 2017). Ranked as 
the 14th leading cause of death worldwide, CKD is a significant cause of morbidity and 
mortality, imposing a substantial global economic and health burden (Webster et al., 
2017). In Canada, national trends in the prevalence of CKD have mirrored global ones 
(Arora et al., 2013). CKD currently affects 12.5% of Canadians, with treatments for end-
stage renal disease accounting for $1.9 billion in health care costs in 2000 (Arora et al., 
2013; Zelmer, 2007). The rising prevalence of CKD in Canada is attributed to the   
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Figure 1.2 Schematic diagram of glomerular filtration. Diagram of the glomerulus 
(left), glomerular capillary (middle), and GFB (right). The afferent arteriole delivers 
blood to the glomerulus and branches within it to form a capillary network (glomerular 
tuft). Each glomerular capillary wall is lined with a GFB. First, blood passes travels 
through the fenestrations between endothelial cells (1), then an extracellular glomerular 
basement membrane (2), and finally a podocyte epithelial layer (3). The plasma filtrate is 
pooled in the Bowman’s capsule and led through the remaining components of the 
nephron, while the ultrafiltrated blood is returned to circulation by the efferent arteriole. 
Image modified from (Tryggvason and Wartiovaara, 2005). 
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increasing level of the aged and overweight in our population; age and weight are both 
inversely correlated to kidney function (Arora et al., 2013; National Kidney Foundation, 
2002). 
1.2.2 Detection and Progression  
1.2.2.1 Diagnosis  
There are several assessments that can be used as a proxy for kidney function and health, 
but diagnosis of CKD usually occurs on the basis of one of two screenings. The first 
diagnostic tool is a urinalysis to detect the degree of proteinuria, which is defined by the 
presence of more than 300 mg of protein in urine with more than 3.5 g of protein per day 
being excreted in nephrotic syndrome. Urinary excretion of protein is a hallmark of 
abnormal kidney filtration; albumin is the most commonly used biomarker for proteinuria 
assessments and the presenting symptom is accordingly known as albuminuria 
(Haraldsson et al., 2008). The standard method for proteinuria detection is a urine 
dipstick test which utilizes a reagent strip device that changes colour if protein is present 
at a level that is above the normal range (Lamb et al., 2009). To further quantify the 
amount of protein present in the urine, a protein to creatinine ratio (UPCR) is used on a 
spot urine sample; a ratio is necessary as it corrects for variations in urinary protein 
concentration due to hydration (Levey et al., 2003). Previously, 24 hour timed urine 
collection were used to measure proteinuria, but the UPCR of a spot urine sample has 
since become the preferred assay (Lamb et al., 2009; Levey et al., 2003).  
The second diagnostic parameter is a measure of the estimated glomerular filtration rate 
(eGFR), which indirectly provides the flow-rate of blood being filtered by the kidney and 
is considered the gold-standard method for diagnosis of CKD (Levey & Coresh, 2012; 
Levey & Inker, 2016). GFR is most commonly determined using an estimation based on 
the 24-hour urinary clearance or serum level of an endogenous filtration biomarker in 
combination with prediction equations that take into account variables such as body size, 
age, and sex (Levey & Inker, 2016; National Kidney Foundation, 2002). The most 
commonly used biomarker for eGFR is creatinine (eGFRcr) (Levey & Inker, 2016). An 
individual’s GFR is determined by two factors: the number of functioning nephrons 
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present and the rate of filtration in each nephron, with the latter being largely dependent 
on the integrity of the GFB (Brinkkoetter et al., 2013; Schwartz & Furth, 2007). A GFR 
of less than 60 mL/minute/1.73m2 over a period of 3 months or longer is sufficient for 
CKD diagnosis (National Kidney Foundation, 2002).  
1.2.2.2 CKD Stages and Treatment 
CKD is classified into five different stages on the basis of GFR, with each successive 
stage corresponding to an increasingly diminished GFR (Table 1.1). Proper evaluation 
and course of action for CKD patients begins with recognizing and identifying the correct 
disease stage and further requires a fundamental understanding of the separate but related 
concepts of diagnosis, disease complications and severity, and risks and comorbidities 
associated with loss of kidney function (National Kidney Foundation, 2002). Treatment 
at stages 1 and 2 is centered around slowing disease progression through the controlled 
management of comorbidities including hypertension and diabetes. At stage 3, other 
complications of decreased GFR, such as anemia, and bone disease, in addition to 
hypertension and diabetes, are targeted for amelioration. By stage 4, once the eGFR drops 
below 30 ml/min/1.73m2, patients should be prepared for kidney replacement therapy 
which is necessary for survival upon progression to stage 5. The final stage of CKD or 
end-stage renal disease (ESRD) is kidney failure that is defined by an eGFR of less than 
15ml/min/1.73m2, and can only be treated by means of dialysis or kidney transplantation 
(National Kidney Foundation, 2002).  
1.2.3 Etiology and Comorbidities   
1.2.3.1 Risk Factors  
The difficulty in the treatment and management of CKD is attributed to its diverse range 
of aetiologies, including genetic, autoimmune, metabolic and toxic, mechanical, 
environmental, and dietary factors (Nogueira et al., 2017). Risk factors for CKD are 
defined by their contribution to the susceptibility, onset, progression, and/or end-stage of 
the disease, with the majority of research being focused on identifying earlier stage risk 
factors (Table 1.2). Susceptibility factors include sociodemographic and genetic factors  
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Table 1.1 CKD stages and prevalence. The five stages of CKD and corresponding 
global and national prevalence rates with the description, GFR threshold, and course of 
action for each stage (below); N/A prevalence estimate not available. Adapted from the 
National Kidney Foundation (2002) with data from (Hill et al. 2016; Arora et al. 2013). 
 
STAGE Pre Stage 1  Stage 2  Stage 3  Stage 4  Stage 5 
Description At 
increased 
risk  
Kidney 
damage 
with normal 
or ↑ GFR 
Kidney 
damage 
with mild ↓ 
GFR 
Moderate ↓ 
GFR 
 
Severe ↓ 
GFR 
 
Kidney 
failure  
 
GFR 
(mL/min/1.73 
m2) 
> 60 (with 
CKD risk 
factors) 
> 90 60-89 
 
30-59  15-29 < 15  
Course of 
Action 
 
Screening; 
control of 
risk 
factors  
Diagnosis 
and 
treatment of 
comorbid 
conditions, 
slowing 
progression, 
CVD risk 
reduction  
Estimating 
progression 
 
Evaluating 
and treating 
complications 
(i.e. 
comorbidities)  
 
Preparation 
for renal 
replacement 
therapy  
Renal 
replacement 
therapy in 
the form of 
dialysis or 
kidney 
transplant  
 
Global 
prevalence 
(above)  
Prevalence in 
Canada  
(italicized, 
below)   
 N/A  3.5% 
6.9% 
3.9% 
2.5%  
7.6% 
2.9% 
0.4% 
N/A 
0.1% 
N/A  
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Table 1.2 Risk factors for CKD. Adapted from National Kidney Foundation (2002) 
with data from (Nahas and Bello, 2005). 
 
Risk Factor Definition  Examples 
Susceptibility  
 
Increases 
susceptibility to 
kidney damage 
Family history or genetic predisposition, 
older age, males, low birthweight and 
infant malnutrition (reduced nephron 
endowment), low income or education, 
ethnic minority status in developed 
countries, low income or education  
Initiation  
 
Directly initiates 
kidney damage  
 
Diabetes, high blood pressure, autoimmune 
diseases, systemic infections, urinary 
stones, drug toxicity (consumption of 
analgesics), smoking, obesity  
Progression  
 
Causes worsening 
kidney damage and 
faster decline in 
kidney function after 
initiation of kidney 
damage  
 
Non-modifiable: genetics, race, age, sex 
(see initiation factors above)  
Modifiable: increased hypertension, poor 
glycemic control in diabetes, smoking, 
obesity  
End-stage  
 
Increases morbidity 
and mortality in 
kidney failure  
Anemia, low serum albumin level, late 
referral, smoking, drug toxicity  
 
 
 
 
 
 
 
11 
 
that predispose individuals to CKD. Initiation risk factors include the two main causes of 
CKD, diabetes and hypertension. If any initiation factors are left untreated or symptoms 
worsen, they transition into progression factors, thereby increasing the rate of progression 
of already established CKD. Other factors such as obesity and smoking have also been 
implicated (National Kidney Foundation 2002; Nahas and Bello 2010). 
1.2.3.2 Comorbidities  
Hypertension and diabetes are widely accepted as the two main causes of CKD in all 
developed and most developing countries (Levey & Coresh, 2012; Webster et al., 2017). 
They are also considered to be significant comorbidities of CKD, with each disease 
exacerbating the progression and outcomes of the other. Section 1.2.5 will examine 
hypertension in the pathophysiology of CKD more closely. Importantly, all three 
collectively increase the risk of cardiovascular disease (CVD) (Wright & Hutchison, 
2009). CVD is a significant outcome to consider in CKD treatment and management, as 
patients with CKD are more likely to die of CVD complications than they are to develop 
kidney failure (National Kidney Foundation, 2002; Sarnak et al., 2003). In fact, in all 
stages of CKD, death is a more likely outcome than progression to ESRD (Jha et al., 
2013). Thus, the amelioration of hypertension and diabetes in the early stages of CKD is 
critical in attenuating both renal and CVD progression (Nahas & Bello, 2010). 
1.2.4 Cell Response to Stress   
1.2.4.1 Renal Fibrosis  
Despite the complex etiology of CKD, the progression of CKD eventually converges into 
common histolopathological and functional manifestations, generally characterized by 
the appearance of a fibrotic phenotype in the tubular, vascular, and glomerular 
compartments of the kidney, termed tubulointerstitial fibrosis, vasclular sclerosis, and 
glomerulosclerosis respectively (Hewitson, 2012). Renal fibrosis is hallmarked by the 
replacement of damaged renal tissues by a scar-like formation as a result of excess 
extracellular matrix (ECM) accumulation and deposition (López-Novoa et al., 2011). The 
cellular response to stress in the kidney is similar to wound-healing processes in other 
tissues, whereby an initial insult leads to the activation of an inflammatory pro-
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proliferative response that involves circulating and migratory immune system cells 
(López-Novoa et al., 2011; Nogueira et al., 2017). However, for reasons that remain 
elusive, this initially restorative inflammatory response becomes deregulated and induces 
uncontrollable and aberrant matrix synthesis and cell proliferation, resulting in tissue 
scarring (Hewitson, 2012; López-Novoa et al., 2011; Nogueira et al., 2017). Depending 
on the location of the fibrotic phenotype, kidney disease can be broadly grouped into 
tubulointerstitial, renovascular, and glomerular diseases (López-Novoa et al., 2011).  
Glomerular diseases, or glomerulopathies, are renal disorders that alter glomerular 
structure and function. They can arise independently or secondary to tubulointerestitial 
and renovascular diseases, but progress significantly faster than tubulointerstitial ones 
(López-Novoa et al., 2011). Glomerulopathies can be defined as either inflammatory, 
caused by systemic and renal infections, or non-inflammatory, caused by chemical or 
mechanical damage such as in the case of diabetes and hypertension (López-Novoa et al., 
2011). The histopathology of glomerulopathies is diverse, but common aberrant 
morphologies include podocyte injury, crescent formations caused by ECM 
accumulation, and focal and segmental glomerulosclerosis (López-Novoa et al., 2011). 
Focal segmental glomerulosclerosis (FSGS) is a glomerulopathy characterized by a 
histologic pattern of glomerular scarring (Rosenberg & Kopp, 2017). At the beginning 
stages of the disease, the glomerulosclerosis is both focal, only limited to a small portion 
of the glomeruli, and segmental, only affecting one section of the glomerulus (D’Agati et 
al., 2014). As the disease progresses, glomerulosclerosis becomes widespread and global 
(D’Agati, 2008). The pathogenesis of FSGS involves two main mechanisms relating to 
podocytes: loss of the filtration barrier and podocyte depletion (D’Agati et al., 2014).  
1.2.4.2 Podocyte Injury  
Podocytes are terminally differentiated epithelial cells that sit on the urinary aspect of the 
GBM facing the Bowman’s capsule, and act as the final barrier of the GFB (Menon et al., 
2012). They have three structural components consisting of the cell body, primary 
processes, and foot processes (Brinkkoetter et al., 2013). The cell body protrudes into the 
urinary space of the Bowman’s capsule and gives rise to primary processes that extend 
down to the capillaries of the glomerulus (Pavenstadt et al., 2003). At the outer surface of 
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the capillaries, the primary processes split into secondary foot processes (FP) that anchor 
and wrap themselves around the capillaries, adhering to the GBM while the cell body 
remains afloat (Brinkkoetter et al., 2013; Kriz et al., 2013). The FP are highly specialized 
contractile structures that interdigitate to form filtration slits between adjacent processes 
(Pavenstadt et al., 2003). A membranous cell-to-cell junction called a slit diaphragm 
bridges the space between filtration slits (Brinkkoetter et al., 2013). Podocytes first 
emerge as a separate cell population in the S-shaped body of the developing nephron 
where cells facing the Bowman’s space are seen to express podocyte-specific markers 
(Brunskill et al., 2011). Importantly for our work, Shroom3 is expressed in the podocyte 
at all stages of life including development and adulthood.  
Podocytes represent the sites of initial injury in nearly all human glomerulopathies and 
animal models of proteinuric glomerular disease, with only a few exceptions (D’Agati, 
2008). Of importance, progressive loss of podocytes is the most frequent cause of end-
stage renal failure (Kriz et al., 2013). Several pathogenic mechanisms underlying 
podocyte injury manifest as ultrastructural changes (Brinkkoetter et al., 2013). 
Specifically, these changes involve the loss of the interdigitating pattern of FP, referred to 
as foot process effacement (FPE) (Kriz et al., 2013). FPE is distinguished by two stages. 
The first stage is marked by the shortening of FP and displacement or loss of the slit 
diaphragms (Kriz et al., 2013). In the second, more progressive stage, complete flattening 
and retraction of the FP into primary processes is observed, eventually merging with the 
cell bodies (Kriz et al., 2013). Because the podocytes are floating cell bodies that only 
attach to the GBM by their foot processes, FPE often results in podocyte detachment in 
conjunction with apoptosis, leaving behind naked areas of the GBM (Kriz et al., 2013). 
These exposed areas then allow for leakage of proteins across the GFB, resulting in 
proteinuria (Kriz et al., 2013).     
A tightly regulated actin cytoskeleton accounts for the core structure of podocytes and the 
assembly and maintenance of their FP (Pavenstadt et al., 2003). The cytoskeletal network 
within FP consists of a dense bundle of actin filaments that extends along the length of 
the foot processes and a shorter, branched cortical network that is found at the cell 
periphery and anchors elements of the slight diaphragm (Reiser & Altintas, 2016). The 
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function of podocytes critically depends on their structural integrity and several studies 
have revealed that injury to podocytes results in a common final pathway of cytoskeletal 
reorganization followed by FPE (Tian & Ishibe, 2016). Thus, proteins that regulate the 
plasticity of the podocyte actin cytoskeleton are essential for the sustained function of the 
GFB (Faul et al., 2007). One such protein is the GTPase family member Ras homolog 
family member A (RhoA) which activates the serine/threonine kinases ROCK1 and 2 
(Amano et al., 2010; Kistler et al., 2012). ROCKs phosphorylate the regulatory light 
chain (RLC) of non-muscle myosin II, which can then form dynamic actomyosin 
contractile networks with actin filaments (Amano et al., 2010). Importantly, ROCKs are 
downstream effectors of Shroom3 that are necessary for its apical constriction function, 
as will be extensively discussed in 1.3. The function of RhoA with respect to podocytes 
appears to be stabilization of FP structure and protection from FPE, and this function is 
dependent on basal RhoA expression. In vitro, overexpression (Zhu et al., 2011) and 
disruption of RhoA (Huang et al., 2016) leads to FPE and podocyte apoptosis in cultured 
podocytes (Kistler et al., 2012).  
Other regulators of the podocyte actin cytoskeleton that have been shown to be crucial to 
proper kidney function include synaptopodin (Asanuma et al., 2005, Asanuma et al., 
2006) and podocalyxin (Schmieder et al., 2004), which are podocyte-specific regulators 
of RhoA. Additionally, Rho guaninine dissociation inhibitor (GDI)-α (Togawa et al., 
1999), as well as Nck1 and Nck2 (Jones et al., 2006; Verma et al., 2006) have been found 
to be essential for maintaining proper podocyte structure. Lastly, α-actinin-4, a mutation 
in which causes familial FSGS in humans (Kaplan et al., 2000) has been shown to induce 
glomerulopathies in vivo upon knockout in mice (Dandapani et al., 2007; Kos et al., 
2003). 
It is therefore not surprising that Shroom3, an established regulator of the actin 
cytoskeleton specifically expressed in podocytes, has been found to be necessary for 
maintenance of podocyte structure. Specifically, loss of Shroom3 and targeted podocyte-
specific disruption of Shroom3 directly results in FPE in mice and zebrafish, respectively 
(Khalili et al., 2016; Yeo et al., 2015).  
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1.2.5 Hypertension and CKD    
Hypertension is the second leading cause of CKD, accounting for 28.4% of all CKD 
cases in the USA (Townsend and Taler 2015). The prevalence of hypertension increases 
with worsening kidney function and has made blood pressure reduction an important 
course of action for slowing CKD progression (Townsend & Taler, 2015). This inverse 
relationship between kidney function and blood pressure (BP) is evidenced by a direct 
correlation between relative risk of developing ESRD and BP severity (Judd & Calhoun, 
2015). In fact, a health screening registry revealed that individuals with a baseline BP of 
180/100 mm Hg were 15 times more likely to progress to ESRD than individuals with a 
baseline BP of 110/70 mm Hg (Tozawa et al., 2003). To fully understand how CKD 
progresses, it is crucial to investigate how hypertension contributes to renal injury.  
1.2.5.1 Pathophysiology  
Hypertensive nephrosclerosis is sclerosis of the kidney caused specifically by 
hypertension and is pathogenically independent of other renal diseases such as diabetic 
nephropathy (Luft, 2000). The extent of renal damage caused by hypertension-related 
mechanisms is determined by the systemic BP load, the degree to which the load is 
transmitted to renal microvasculature, and local tissue susceptibility factors to injury 
resulting from increased pressure including genetic factors, pre-existing glomerular 
hypertrophy and structural integrity of the podocyte layer (Ravera, 2006). 
Under normal conditions, increases in systemic BP are controlled by autoregulatory 
mechanisms such that renal blood flow and glomerular capillary pressure are maintained 
relatively constant, thereby preventing the transmission of the BP load to renal 
microvasculature (Bidani & Griffin, 2004; Ravera, 2006). However, under chronic 
hypertensive conditions, the autoregulatory mechanism exceeds its threshold and 
increases in systemic BP directly induce an increase in renal blood flow and capillary 
pressure, allowing the BP load to reach the renal microvasculature (Bidani & Griffin, 
2004). The increase in glomerular capillary pressure as a result of increased systemic 
blood pressure is termed glomerular hypertension (Endlich & Endlich, 2012). Glomerular 
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hypertension causes mechanical distension of the capillary tuft causing it to expand, 
resulting in glomerular hypertrophy (Endlich & Endlich, 2012).  
Glomerular hypertrophy is necessarily accompanied by a stretch in the overlying foot 
processes, initially functioning as an adaptive response (Kretzler et al., 1994). This causes 
reorganization of the actin cytoskeleton, ultimately resulting in FPE and detachment of 
the podocyte from the GBM, an inevitable result of the mechanical and shear forces 
imposed by the increased pressure load reaching the glomerulus (Nogueira et al., 2017; 
Pavenstadt et al., 2003). Damage to podocytes, in turn, leads to increased leakage of 
proteins across the GFB. This explains why proteinuria is almost always observed in 
concert with hypertension in CKD patients and why proteinuria is an important 
prognostic factor for patients with hypertension (Bakris, 2005). This also explains why 
hypertension increases the risk of developing ESRD as progressive loss of podocytes is 
the most frequent cause of ESRD (Judd & Calhoun, 2015; Kriz et al., 2013).   
Sustained podocyte injury has devastating outcomes that perpetuate progressive renal 
dysfunction. Upon initial insult to the glomerulus, a focal lesion develops and triggers 
apoptosis or detachment of podocytes and subsequent activation of the inflammatory 
response and fibrotic processes (López-Novoa et al., 2011). Fibrotic processes promote 
aberrant ECM synthesis in the spaces left behind by the podocytes which creates a 
connective pathway between the Bowman’s capsule and intersititium that allows the 
protein-rich ultrafiltrate to access other glomeruli and tubules to induce further damage 
(López-Novoa et al., 2011). Since podocytes are terminally differentiated, they cannot 
regenerate and thus it is believed that glomerular injury can be initiated from a single 
injured podocyte that spreads the injury to neighbouring intact podocytes (cell-to-cell-
spreading), setting up a vicious cycle that culminates into glomerulosclerosis (D’Agati, 
2008; Fogo, 2007; Nagata, 2016).  
Numerous mouse models have provided evidence for the critical role of podocytes in the 
pathogenesis of glomerulopathies, where podocyte-specific injury initiated by an 
extrinsic insult resulted in progressive sclerosis (Fogo, 2007). In one such model, the 
extrinsic insult was an injection of a toxin, with mice expressing the toxin receptor under 
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the control of a podocyte-specific promoter (Wharram et al. 2005). In these mice 
subjected to podocyte-injury, the number of depleted podocytes correlated closely with 
the severity of disease. Specifically, depletion of more than 40% of the podocyte 
population led to overt FSGS accompanied by high-grade proteinuria and renal 
insufficiency, establishing a disease threshold (Wharram et al. 2005). In another model, 
using chimeric mice, where only a portion of the podocytes were expressing the toxin 
receptor, podocyte injury and apoptosis spread to neighbouring podocytes that lacked the 
toxin receptor and initially escaped the extrinsic insult (Matsusaka et al., 2011). This 
provides support for the cell-to-cell spreading model, whereby a small subset of injured 
podocytes can propagate the initial injury to non-injured podocytes in a domino-like 
effect, resulting in glomerulosclerosis (Matsusaka et al., 2011).  
The ability of hypertension to induce podocyte damage and progress into 
glomerulosclerosis has also been demonstrated by several models. In vitro, mechanical 
stretching of conditionally immortalized mouse podocytes facilitated by a computer-
assisted stretch apparatus results in enhanced expression of proinflammatory cytokines 
including transforming growth factor beta (TGF-ß) (Durvasula et al., 2004). In vivo, 
using a  uninephrectomy-desoxycorticosterone-trimethylacetate (UNX-DOCA) rat model 
of chronic hypertension and progressive renal disease, significant increases in blood 
pressure were observed 3 weeks after surgical kidney excision (Kretzler et al., 1994). By 
7 weeks, these mice exhibit hypertrophied glomeruli and subsequent development of 
glomerulosclerosis. Common to all destructive glomerular profiles observed in the UNX-
DOCA hypertensive rats was podocyte detachment, FPE, and pseudocyst formation 
directly leading up to glomerulosclerosis. While mesangial cell expansion was also 
frequently observed, no evidence for the pathological sequence of cell shape change and 
subsequent glomerulosclerosis was found (Kretzler et al., 1994). Mesangial cells function 
to structurally support the glomerular capillaries through their production of mesangial 
matrix components including collagen and fibronectin (Haraldsson et al., 2008).  
Interestingly, an unrelated study found that upon induction of podocyte injury, both 
endothelial and mesangial cells also exhibited cellular responses to stress marked by cell 
swelling and expansion of the ECM, which was then followed by the development of 
glomerulosclerosis (Ichikawa et al., 2005). Furthermore, the degree of endothelial and 
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mesangial cell response was dependent on the magnitude of podocyte injury, suggesting 
that podocytes may be capable of propagating injury to other cell types (Ichikawa et al., 
2005). Thus, it could be the case that the mesangial cell expansion described in the study 
by Kretzler et al. (1999), was induced by podocyte damage.  
A study using Dahl salt-sensitive (DS) rats that develop hypertension when fed a high-
salt diet, foot process effacement and fusion were observed as early as 2 weeks into salt-
loading concomitant with the onset of hypertension and before the development of 
glomerulosclerosis (Nagase et al., 2006). Furthermore, the degree of podocyte damage 
and consequent proteinuria was exacerbated with increasing exposure to the high-salt diet 
and manifested into glomerulosclerosis by 6 weeks. From these models of hypertensive 
renal injury, a common pattern of hypertension-induced podocyte damage characterized 
by FPE, cell body attenuation, bare areas of the GBM left behind by podocyte 
detachment and apoptosis, and formation of pseudocysts has emerged (Figure 1.3) 
(Endlich & Endlich, 2012).  
1.2.6 Genome-Wide Association Studies (GWAS) 
In keeping with other chronic multifactorial diseases, CKD is laden with complex 
aetiologies and comprises various environmental and lifestyle factors as well as an 
inherited component of susceptibility (Smyth et al., 2014). This inherited susceptibility 
usually exists in the form of genetic variants in the DNA sequence; identifying these 
susceptible disease variants is a central goal of genome-wide association studies (GWAS) 
(Bush & Moore, 2012; Smyth et al., 2014). Over the past decade, GWAS have been 
invaluable in elucidating the genetic component underlying CKD (Wuttke & Köttgen, 
2016). GWAS analyze hundreds of thousands of single-nucleotide polymorphisms 
(SNPs) from across the human genome in order to find variants that are correlated to a 
particular disease or disease phenotype (Manolio, 2010). In the field of nephrology, 
GWAS have focused on identifying susceptibility variants associated with CKD 
aetiologies such as membranous nephropathy as well as CKD-defining traits such as 
eGFR and urinary albumin to creatinine ratio (UACR) (Wuttke & Köttgen, 2016). 
GWAS of CKD-defining traits have been conducted in whole populations rather than in  
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Figure 1.3 Podocyte injury induced by hypertension. Schematic diagram of a normal 
podocyte (left) and injured podocyte (right). Glomerular hypertrophy is induced by a 
sustained elevation in systemic blood pressure above a threshold causing the podocyte to 
also stretch and expand. In addition to podocyte hypertrophy, other injuries include: 1) 
Foot process effacement 2) pseudocyst formation 3) cell body attenuation 4) detachment 
and/or apoptosis resulting in naked GBM areas. Image modified from (Kriz et al., 2013). 
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case control studies like the GWAS of CKD aetiologies, making them more applicable to 
the general public (Wuttke & Köttgen, 2016). One gene that has consistently been 
identified by these GWAS as having a strong association with kidney function and 
disease is SHROOM3.   
Meta-analyses of prevalent CKD and CKD-defining traits eGFRcr and eGFRcys from four 
large random populations of the Cohorts for Heart and Aging Research in Genomic 
Epidemiology (CHARGE) consortium found SHROOM3 to have strong associations with 
all 3 measured parameters (Köttgen et al. 2009), only second to uromodulin (UMOD), a 
gene already established to play a role in CKD (El-Achkar et al., 2008; Lhotta, 2010; 
Pfistershammer et al., 2007; Vyletal et al., 2010a). These results were later replicated in a 
follow-up study of participants of European ancestry from 20 large population-based 
studies as well as in an independent consortium of European participants from 9 studies  
(Chambers et al., 2010; Köttgen et al., 2010). A separate study on five populations from 
the European Special Population Research Network (EUROSPAN) found a strong 
association between SHROOM3 and serum creatinine levels, further confirming previous 
GWAS findings (Pattaro et al., 2010). While these GWAS identified genetic risk loci 
related to eGFR and prevalent CKD, defined by a eGFR < 60 ml/min/1.73m2 at a single 
time point, they did not address whether the identified loci were involved in the initiation 
of CKD or in the progression of CKD to ESRD (Böger et al., 2011). To that end, a 
separate GWAS sought to determine whether the previously identified genetic loci 
associated with eGFR and prevalent CKD were also associated with initial CKD 
development and risk for progression to ESRD. Although SHROOM3 was not found to 
be correlated with ESRD, it was found to be strongly associated with initiation of CKD 
(Böger et al., 2011).  
Another GWAS interested in identifying loci associated with serum magnesium, 
potassium, and sodium concentrations found a SNP in SHROOM3 that strongly 
correlated to serum magnesium concentrations and clinical hypomagnesemia in European 
descent participants from the CHARGE Consortium (Meyer et al., 2010). The kidney is 
an important regulator of ionic serum concentrations and serum magnesium has been 
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implicated in hypertension and diabetes, the main causes of CKD (Levey & Coresh, 
2012; Meyer et al., 2010).  
In light of these findings, a successive GWAS sought to assess whether the loci 
correlated to eGFR as identified by Köttgen et al. were also associated with albuminuria 
and urinary albumin-to-creatinine ratio (UACR) (Ellis et al., 2012). Albuminuria is the 
strongest known risk factor for the progression of CKD and UACR has a known inverse 
relationship with eGFR, with a decreased eGFR corresponding to an increased UACR. 
Participants of European ancestry from the CKDGen Consortium cohort and of African 
ancestry from the CARe Renal Consortium were tested for 16 eGFR-associated SNPs for 
association with UACR and albuminuria. In populations from the CKDGen Consortium 
and CARe Renal Consortium, SHROOM3 was the only locus observed to have 
associations with UACR and albuminuria, respectively. Surprisingly, the association of 
SHROOM3 to lower eGFR corresponded to a decreased UACR. This deviation from the 
typical inverse relationship may have two plausible explanations: SHROOM3 may be 
exerting pleiotropic effects or is interacting with mechanisms that substantiate both a 
higher eGFR and a higher UACR, as in the case of hyperfiltration states (diabetes, 
hypertension, hyperuricemia) (Ellis et al., 2012). Given the role of hypertension and 
diabetes in the etiology of CKD, the latter is highly likely. The interaction between eGFR 
and albuminuria in diabetes was studied in patients with Type 2 diabetes from the 
Genetics of Diabetes Audit and Resaerch Tayside (GoDARTS) study. Results from the 
GWAS found that SHROOM3 was strongly associated with eGFR in type 2 diabetes, and 
this association was specific to patients with diabetes accompanied by albuminuria 
(Deshmukh et al., 2013). 
Despite the numerous GWAS postulating a correlation between SHROOM3 and CKD, 
only recently was Shroom3’s role in the kidney characterized. While pathogenic 
mutations in UMOD, the other candidate gene identified by GWAS, are known to cause 
autosomal dominant kidney diseases in humans including medullary cystic kidney 
disease 2 and familial juvenile hyperuricemic nephropathy, the potential role of 
SHROOM3 in the pathophysiology of disease is still an emerging area that remains 
relatively incomplete (Vyletal et al., 2010; Zhu et al., 2002).  
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1.3 Shroom3 
1.3.1 Identification   
Shroom3 encodes for the actin-binding protein Shroom3 that was first identified in mice 
by gene trap mutagenesis as part of an ongoing screen for novel genes implicated in 
embryonic development (Hildebrand & Soriano, 1999). Gene trapping is a mutagenesis 
strategy that involves the insertion of a vector containing a splice acceptor site in front of 
a reporter such that if it inserts in an intron of a gene, it will express the reporter and 
potentially disrupt the gene at the insertion site (Stanford et al., 2001). This reporter 
becomes under the control of the trapped gene’s endogenous promoter, allowing for 
accurate reporting of that gene’s expression pattern. Depending on where the insertion 
takes place, the endogenous gene may no longer produce a functional protein. 
Sequencing of flanking genomic sequences upstream or downstream of the insertion site 
(depending on the type of gene trap vector used), allows one to then identify the gene trap 
insertion loci (Friedel & Soriano, 2010). Using this technique and the B-galactosidase 
reporter gene, Hildebrand and Soriano (1999) were able to characterize a novel recessive 
gene trap mutation that caused fully penetrant exencephaly in mice homozygous for the 
gene trap allele, herein referred to as Shroom3Gt/Gt. Exencephaly is an embryonically 
lethal neural tube defect (NTD) resulting from failure of neural tube closure in which the 
brain protrudes out of the skull (Hildebrand & Soriano, 1999; Müller & O’Rahilly, 1991). 
Due to the appearance of the brain “mushrooming” from the skull, the mutation was 
accordingly named Shroom (shrm) and later renamed Shroom3 in light of the presence of 
proteins with sequence similarities (Hagens et al., 2006; Hildebrand & Soriano, 1999) 
(see 1.3.2  below). The severity of the recessive lethal phenotype established Shroom3 as 
a critical factor for neural tube closure and subsequent studies primarily focused on 
defining its functional role in that process.  
1.3.2 Shroom3 Protein Structure  
1.3.2.1 Conserved Domains  
The full-length human Shroom3 protein consists of 1996 amino acids and has a 
molecular mass of 217 kDa. In mice, there are two putative protein products of Shroom3 
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encoded by two different transcripts: a long isoform comprised of 1986 amino acids and a 
short isoform comprised of 1808 amino acids (Hildebrand & Soriano, 1999). Shroom3 is 
characterized by a specific linear array of sequence motifs that outlines three distinct 
domains (Figure 1.5): a N-terminal PSD/Dgl/ZO-1 (PDZ) domain, a centralized 
Apx/Shrm (ASD1) domain, and a C-terminal Apx/Shrm (ASD2) domain (Hildebrand & 
Soriano, 1999). The ASD1 domain directly binds to actin, while the ASD2 domain is 
characterized by a three-segmented coiled-coil region that binds to Rho-associated 
kinases 1 and 2 (ROCK1 and ROCK2) (Dietz et al., 2006; Hildebrand & Soriano, 1999; 
Mohan et al., 2012). The two ASD domains are critical for the function of Shroom3; 
deletion of either of the two domains leads to ablation of Shroom3-induced apical 
constriction. The PDZ domain of Shroom3 is not well-studied but is believed to be 
dispensable for apical constriction activity as the short isoform of Shroom3 in mice that 
lacks the PDZ domain phenocopies the long Shroom3 isoform containing the PDZ 
domain (Hildebrand & Soriano, 1999). These findings were recapitulated in vitro with 
deletion of PDZ having no effect on the ability of Shroom3 to drive apical constriction 
(Dietz et al., 2006; Haigo et al., 2003).  
1.3.2.2 Shroom Family   
Shroom3 is a highly conserved protein with homologs found in 186 species including 
vertebrates such as the chick, mouse, chimpanzee, Xenopus, dog, cow, and rat as well as 
invertebrates such as Drosophila and tunicate. The ASD domains of Shroom3 share no 
homology with any other known proteins and the conservation of at least one of the ASD 
domains is the defining feature of the Shroom family of proteins that Shroom3 belongs to 
(Hagens et al., 2006; Hildebrand & Soriano, 1999). The Shroom family consists of four 
family members that are numbered based on the order that they were identified (Hagens 
et al., 2006). Originally, the nomenclature for Shroom proteins was based on its 
discovery in Xenopus (Hagens et al., 2006). Correspondingly, Shroom1 was previously 
named apical protein in Xenopus (Apx) and Shroom2 was previously named apical 
protein Xenopus-like (APXL) as it was thought to be the human orthologue of Apx, but it 
has since been characterized as a distinct protein (Hagens et al., 2006). Shroom3 was 
previously named Shroom and Shroom4 was previously named KIAA1202; Shroom4 is 
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Figure 1.4 Conserved domains of Shroom3. Schematic diagram of Shroom3’s three 
conserved domains: a N-terminal PSD/Dgl/ZO-1 (PDZ) domain, a centralized Apx/Shrm 
(ASD1) domain and a second C-terminal Apx/Shrm (ASD2) domain.  
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the only Shroom family member that does not possess both ASD domains, having only 
the ASD2 domain (Hagens et al., 2006; Lee et al., 2009). Collectively, the Shroom family 
proteins have been broadly linked to the regulation of cellular architecture through their 
interactions with cytoskeletal elements including actin filaments and microtubules (Lee et 
al., 2009). At this time, Shroom3 is unique in that it is the only family member that is 
known to be both necessary and sufficient for driving a specific cell shape change, 
namely apical constriction, required for the morphogenesis of epithelial tissues during 
development (Dietz et al., 2006).  
1.3.3 Cellular Functions of Shroom3 and Mechanisms of Action  
1.3.3.1 Apical Constriction  
The cytoskeleton is a complex network consisting of actin filaments, microtubules, and 
intermediate filaments that establishes the structural framework of cells (Fletcher & 
Mullins, 2010). The regulation of the cytoskeletal elements underlies several aspects of 
cellular physiology including cell polarity, volume, division, and migration (Bezanilla et 
al., 2015; Fletcher & Mullins, 2010). Importantly, the dynamic properties of the actin 
cytoskeleton generate forces that enable cells to change shape and become motile 
(Bezanilla et al., 2015). The coordination of these cell shape changes and movements can 
lead to global alterations in tissue morphology (Heisenberg & Bellaïche, 2013; Martin & 
Goldstein, 2014). 
Epithelial tissues rely on the coordinated cellular behaviors of their constituent cells in 
order to undergo remodeling events that are essential to tissue morphogenesis during 
development as well as maintaining tissue homeostasis throughout life (Martin & 
Goldstein, 2014). One important cell shape change that takes place in epithelial cells that 
are polarized along their apicobasal axis is apical constriction (Heisenberg & Bellaïche, 
2013; Martin & Goldstein, 2014). Apical constriction is characterized by the narrowing 
of the cell surface at the apical end, inducing the cell to change from a columnar shape to 
a wedge shape (Martin & Goldstein, 2014). This occurs through the contraction of a 
filamentous actin (F-actin) meshwork at the apical surface by myosin (Sawyer et al., 
2010). In a developmental context, tightly orchestrated apical constriction in distinct 
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populations of cells allows for bending and invagination of epithelial sheets, which are 
processes that govern neural tube closure, gut morphogenesis, and lens placode formation 
(Chung et al., 2010; Hildebrand & Soriano, 1999; Plageman et al., 2010; Sawyer et al., 
2010). Additionally, apical constriction of epithelial cells has also been shown to 
contribute to cell ingression from epithelial tissue often accompanying epithelial-
mesenchymal transition (EMT) (Anstrom, 1992; Williams et al., 2012). In a homeostatic 
context, apical constriction is involved in the extrusion of apoptotic cells from epithelial 
sheets as well as wound healing and closure (Davidson et al., 2002; Toyama et al., 2008). 
The critical importance of apical constriction to a variety of cellular and morphogenetic 
events has necessitated a greater understanding of its regulation.  
It is now well established that Shroom3 is necessary and sufficient for inducing apical 
constriction in at least a significant subset of epithelial cells. Shroom3 achieves this 
through its two ASD domains that allow for apical subcellular localization as well as 
activation of the cellular machinery required to generate the mechanical force for 
contraction (Dietz et al., 2006; Hildebrand & Soriano, 1999; Nishimura & Takeichi, 
2008). The ASD1 domain of Shroom3 directly binds to F-actin stress fibers, recruiting 
them to the apical surface and bundling them (Hildebrand, 2005; Hildebrand & Soriano, 
1999). Prior to this, Shroom3 is recruited to the apical surface by RhoA, which is part of 
the Rho GTPase family of proteins that are broadly involved in organization of the actin 
cytoskeleton (Plageman et al., 2011; Sit & Manser, 2011). RhoA itself is activated upon 
catalytic conversion of its inactive GDP subunit to the active GTP form (Rossman et al., 
2005). Concerning Shroom3 regulation, RhoA is specifically activated by the Rho 
guanine nucleotide exchange factor (GEF) Trio (Plageman et al., 2011).  
Apical recruitment of Shroom3 by RhoA causes subsequent colocalization of Shroom3 
and F-actin at the apical junctional complexes (AJCs) (Dietz et al., 2006). Once 
colocalized with actin at the AJCs, the ASD2 domain directly binds to Rho-associated 
kinases ROCK1 and 2 and recruits them to AJCs (Nishimura & Takeichi, 2008). ROCK1 
and 2 possess a highly conserved coiled-coil Shroom3 binding domain while the ASD2 
domain is composed of three canonical coiled-coil segments; the two domain structures 
allow for the formation of the Shroom3-ROCK complex (Mohan et al., 2012; Mohan et 
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al., 2013). In addition to its Shroom3 binding domain, ROCKs also possess a RhoA 
binding domain, and binding of RhoA was believed to be involved in ROCK activation 
(Plageman et al., 2011). However more recently, it has been shown that the ASD2 
domain of Shroom3 can directly stimulate ROCK activity independently of RhoA 
(Zalewski et al., 2016). ROCKs are serine/threonine kinases that function as upstream 
regulators of non-muscle myosin II (Amano et al., 2010). Once recruited to the AJCs, 
ROCKs phosphorylate the myosin regulatory light chain (mRLC), activating the 
molecular motor non-muscle myosin II. Non-muscle myosin II then binds to actin 
filaments at the AJCs to assemble a contractile actomyosin network that contracts the cell 
at the apical surface, resulting in shrinkage of the apical end and thus apical constriction 
(Sawyer et al., 2010; Shutova et al., 2012). Deletion constructs lacking either of the two 
ASD domains abrogates Shroom3’s ability to induce apical constriction in epithelial cells 
(Dietz et al., 2006; Haigo et al., 2003; Hildebrand, 2005).  
1.3.3.2 Apicobasal Elongation   
In addition to altering cellular architecture through its association with the actin 
cytoskeleton, Shroom3 also functions to regulate the microtubule cytoskeleton (Lee et al., 
2007). Microtubules (MTs) are non-covalent polymers that consist of repeating α/β-
tubulin heterodimers (Wiese & Zheng, 2006). Like actin, microtubules are highly 
dynamic and are involved in vital cellular processes such as cell transport, motility, 
division, as well as cell shape change (Nogales, 2001). Their dynamic nature is rooted in 
their ability to constantly switch between phases of growing and shrinking (Nogales, 
2001). During MT assembly, the α/β-tubulin heterodimers align themselves in a head-to-
tail fashion with the α tubulin on the slow growing “minus” end and the β-tubulin on the 
fast growing “plus” end (Wiese & Zheng, 2006). Nucleation of MTs mainly takes place 
at microtubule-organizing centers (MTOCs), which are located at the minus end 
(Nogales, 2001). Critical to the regulation of MT nucleation is the MTOC-associated 
protein γ-tubulin (Conduit, 2016). γ-tubulin forms a γ-tubulin ring complex that is 
recruited to MTOCs in order to catalyze MT assembly (Conduit, 2016).  
An essential cell shape change that is regulated by MT assembly is apicobasal elongation 
(Kondo & Hayashi, 2015). In polarized epithelial cells, MT assembly occurs along the 
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apicobasal axis with the plus end of MTs pointing towards the basal end (Kondo & 
Hayashi, 2015). This apicobasal orientation of MTs is believed to regulate height control 
(Kondo & Hayashi, 2015). Shroom3 is sufficient to drive parallel MT assembly along the 
apicobasal axis in epithelial cells by controlling the distribution of γ-tubulin such that it is 
accumulated at foci at the apical end of cells (Lee et al., 2007). However, Shroom3 does 
not directly bind γ-tubulin nor does it alter the total γ-tubulin levels in tissues or non-
apical MT arrays, suggesting that Shroom3 indirectly recruits γ-tubulin to the apical side 
and promotes assembly of a discrete population of MTs aligned apicobasally (Lee et al., 
2007).  
As mentioned previously, apical constriction contributes to epithelial invagination during 
embryogenesis. This decrease in apical surface area of epithelial cells is actually 
preceded by an increase in cell height (Kondo & Hayashi, 2015). Specifically, assembly 
of MTs along the apicobasal axis of cells causes elongation and a reduction in apical and 
basal surface areas, inducing cells to change from a cuboidal-shape to a columnar-shape 
(Kondo & Hayashi, 2015). This apicobasal elongation is subsequently followed by apical 
constriction, causing a decrease in the apical surface area of cells, and the adoption of a 
wedge-shape (Kondo & Hayashi, 2015). These two cellular processes are independent 
events that follow a conserved spatiotemporal pattern during neural tube formation 
(Kondo & Hayashi, 2015; Suzuki et al., 2012). Moreover, Shroom3 can mediate the two 
processes independently with apicobasal elongation occurring in the absence of apical 
constriction in some tissues and vice versa (Lee et al., 2007). The apical localization of 
both γ-tubulin and actin to drive MT and actin-based cell shape changes has established 
Shroom3 as a critical regulator of the cytoskeletal dynamics.   
1.3.4 Tissue-Specific Activities of Shroom3  
1.3.4.1 Neural Tube Closure  
Neural Tube Formation. The pivotal work of Hildebrand and Soriano (1999) established 
Shroom3 as a novel regulator of neural tube morphogenesis. Herein, Shroom3’s most  
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Figure 1.5 Schematic illustration of Shroom3’s proposed mechanisms for apical 
constriction and apicobasal elongation.  Activation of RhoA by Trio causes recruitment 
of Shroom3 to the apical surface. At the apical surface, Shroom3 binds to actin stress 
fibers with its ASD1 domain and bundles them. Its ASD2 domain binds to ROCK1 & 2, 
causing them to localize to the apical surface where they phosphorylate the non-muscle 
myosin II regulatory light chain. Active non-muscle myosin II then moves along actin 
filaments and causes contraction at the apical surface, resulting in apical constriction. 
Shroom3 can also recruit γ-tubulin to the apical surface, driving parallel assembly of MT 
arrays along the apicobasal axis, causing apicobasal elongation.  
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discernible function, inducing apical constriction in epithelial cells, was demonstrated by 
the fully penetrant exencephaly phenotype of Shroom3Gt/Gt mice. Apical constriction 
during neurulation is not uniformly applied to all neural plate cells, rather it occurs in 
discrete cell populations known as hingepoint cells (Haigo et al., 2003; Sawyer et al., 
2010). Shroom3 is required for neural tube closure as it facilitates formation of dorsal 
lateral and medial hingepoints, which apically constrict to facilitate bending of the 
neuroepithelium towards the dorsal midline thereby forming the neural tube (Haigo et al., 
2003). Concomitant with apical constriction during neural tube formation, Shroom3 also 
functions to increase cell height by inducing apicobasal elongation via assembly of MT 
arrays (Lee et al., 2007). Besides exencephaly, other consequences of failure of neural 
tube closure in Shroom3Gt/Gt mice were morphologically manifested as acrania, facial 
clefting, and spina bifida (Hildebrand & Soriano, 1999).  Of note, mice containing only 
one copy of the gene trap allele (Shroom3+/Gt) displayed partial (8%) penetrance of the 
exencephaly phenotype. Furthermore, although Shroom3 is expressed along the entire 
neural tube, much of the spinal cord still closes in mice lacking functional Shroom3 
indicating that other mechanisms also facilitate neural tube closure.  
Shroom3’s ability to induce apical constriction during neural tube closure appears to be 
regulated by Lulu (also known as Epb41l5) (Chu et al., 2013). Lulu is a four-point-one, 
ezrin, radixin, moesin (FERM) domain containing protein and is critical for neurogenesis, 
with a loss of function mutation in mice causing aberrant neural plate morphology and 
failure of neural tube closure (Lee et al., 2007). In Xenopus, loss of endogenous Lulu 
leads to a significant decrease in Shroom3-induced apical constriction, a consequence 
attributed to reduced apical Shroom3 localization, with nearly all of Shroom3 remaining 
cytoplasmic rather than accumulating at the AJCs (Chu et al., 2013). On the contrary, co-
injection of Shroom3 with Lulu resulted in enhanced apical constriction, indicating that 
the two proteins may be acting synergistically to induce apical constriction.  
Planar Cell Polarity (PCP). Planar polarity is the establishment of polarity in any two-
dimensional tissue that is orthogonal to apicobasal polarity (Zallen, 2007). In order to 
achieve planar polarity in tissues, the constituent cells must become asymmetric and 
coordinate their asymmetries with one another, a function that is regulated by the PCP 
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pathway (Zallen, 2007). Establishment of planar polarity is a necessary prerequisite for 
the cell shape changes involved in tissue morphogenesis, including apical constriction. 
The “core” PCP pathway confers polarity via noncanonical (β-catenin-independent) Wnt 
signaling and involves the transmembrane proteins Frizzled (Fzd), Van Gogh (Vang; also 
known as Strabismus/Stbm), and Celsr as well as the cytoplasmic proteins Dishevelled 
(Dvl), Prickle (Pk), and Inversin (Adler et al., 1997; Chae et al., 1999; Feiguin et al., 
2001; Gubb & García-Bellido, 1982; J Taylor et al., 1998; Theisen et al., 1994; Usui et 
al., 1999; Vinson et al., 1989; Wolff & Rubin, 1998). Transduction of Wnt signaling 
occurs upon binding of Wnt ligands to Frizzled receptors, leading to activation of 
Dishevelled (Dvl) (Komiya & Habas, 2008). Active Dvl can then modify the actin 
cytoskeleton through activation of ROCK, which phosphorylates non-muscle myosin II 
(Habas et al., 2001; Marlow et al., 2002; Winter et al., 2001). The PCP pathway requires 
asymmetric localization of its key players and studies have shown that both Celsr and Dvl 
are planar polarized, localizing to the AJCs along the mediolateral axis (Tamako 
Nishimura et al., 2012). This subsequently causes polarization of ROCK and 
phosphorylated mRLC.  
During neurulation, convergent extension of the neural plate that precedes neural plate 
bending critically depends on the PCP pathway (Wallingford et al., 2002). Convergent 
extension (CE) is driven by tightly coordinated cell intercalation, which proceeds through 
the formation of intermediary multicellular units known as rosettes (Williams et al., 
2012). Apical constriction of distinct cell clusters within the primordium of the posterior 
lateral line is the primary mechanism underlying rosette assembly, a process that relies on 
FGF signaling (Lecaudey et al., 2008; Nechiporuk & Raible, 2008). Shroom3 is 
necessary for rosette formation in zebrafish by activating apical actomyosin contractility 
through ROCK and non-muscle myosin II downstream of FGF signaling (Ernst et al., 
2012). Further, FGF is both necessary and sufficient for Shroom3 expression in the 
posterior lateral line, but not in any other regions, suggesting that FGF regulation of 
Shroom3 is specific to rosette formation (Ernst et al., 2012). These findings were 
recapitulated in Drosophila, where loss of functional Shroom led to disruption of rosette 
assembly accompanied by a decrease in ROCK and myosin planar polarity, decreased 
junctional tension, and consequent abrogation of CE (Simões et al. 2014).      
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Similar findings in zebrafish and Drosophila were also seen in mice that showed embryos 
lacking functional Shroom3 possessed rosettes with lower complexity, though they did 
not display a decrease in the total number of rosettes (McGreevy et al., 2015). This 
implicated that Shroom3 is not required for initial rosette formation but is necessary for 
formation of higher order rosettes, which are believed to facilitate apicobasal elongation 
and apical constriction at mediolateral junctions in the neural plate. Significant to this 
study was the finding that Shroom3 acts downstream of the PCP pathway in order to 
drive these cell shape changes required for CE in mice, in a manner dependent on Dvl2. 
First, genetic interactions between Shroom3 and PCP components Vangl and Wnt5a were 
observed in mice as double mutants exhibited exacerbated NTDs and CE defects 
(McGreevy et al., 2015). Additionally, Shroom3’s role in the PCP pathway appears to 
require the activity of Dvl2. The DEP domain of Dvl2 and an uncharacterized N-terminal 
region of Shroom3 were found to form a complex that is necessary for colocalization of 
Shroom3 and ROCK along mediolateral cell junctions in the neural plate, where it is 
postulated that apical constriction leads to higher order rosette assembly and subsequent 
induction of CE (McGreevy et al., 2015). Thus, Shroom3 appears to control various 
events during neurulation.       
1.3.4.2 Neuronal Growth and Repair    
Besides its role during neural tube closure, Shroom3 has been implicated in the adult 
vertebrate central nervous system (CNS) function. The inability of mature axons to 
spontaneously regenerate after injury is the central limiting factor underlying CNS 
damage and neurodegenerative diseases (Yiu, 2006). In the adult CNS, neural repair and 
regeneration is repressed by proteins that inhibit axon outgrowth (Dickson, 2010). One 
such protein is the multidomain scaffold protein Plenty of SH3s (POSH) composed of 
four Src homology (SH3) domains (Taylor et al., 2008). POSH promotes neuronal death 
by stimulating the proapoptotic JNK pathway (Xu et al., 2003). Shroom3 directly 
interacts with POSH’s third SH3 domain (SH3-3) to jointly inhibit axon outgrowth in a 
manner that is dependent on ROCK (Taylor et al., 2008). Injection of either Shroom3 or 
POSH RNAi into neurons derived from P19 cells, resulted in exuberant axon outgrowth 
(Taylor et al., 2008). Interestingly, repression of myosin II function reversed the axon 
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outgrowth seen in cells injected with Shroom3 or POSH RNAi. Thus, while myosin II 
activation is necessary for Shroom3 induced apical constriction, myosin II repression is 
required for POSH-Shroom3-mediated axon outgrowth inhibition (Taylor et al., 2008).  
NogoA is another axon outgrowth inhibitory protein and possesses an inhibitory C-
terminal domain, Nogo66 (Fournier et al., 2001). Nogo66 interacts with two different cell 
surface receptors, Nogo receptor 1 (NgR1) (Fournier et al., 2001) and paired 
immunoglobulin-like receptor B (PirB) (Atwal et al., 2008), that confer inhibitory signals 
through two distinct pathways. POSH has been found to act as a vital intracellular signal 
transducer in PirB-mediated Nogo66 neurite outgrowth inhibition by forming a complex 
with Shroom3, ROCK, and leucine zipper kinase (Dickson et al. 2010; Taylor et al. 
2008). Blocking the interaction between Shroom3 and ROCK circumvents PirB-mediated 
Nogo66 axon outgrowth inhibition (Dickson et al., 2015). Utilizing an ELISA platform, a 
chemical inhibitor of Shroom3-ROCK interaction was identified (Dickson et al., 2015). 
This inhibitory compound, CCG-17444, irreversibly blocked binding of Shroom3 to 
ROCK, leading to release of axon outgrowth inhibition and increased neurite length, to a 
degree similar to the effect of RNAi-mediated POSH or Shroom3 repression (Dickson et 
al., 2015). Of importance, CCG-17444 fails to enhance neurite length in neurons lacking 
functional Shroom3 or POSH, suggesting that it acts on the same pathway as the two 
proteins. The ability to pharmacologically induce neurite outgrowth by blocking an 
inhibitory axon outgrowth pathway involving Shroom3 is potentially a tremendous first 
step in the uncovering of novel therapeutic strategies for CNS injury.  
1.3.4.3 Lens Development   
Early lens morphogenesis occurs through the formation of the lens placode that 
invaginates to form the lens pit and optic cup. The invagination of the lens placode is 
reliant on Shroom3 induced apical constriction of the epithelial cells of the prospective 
lens pit (Plageman et al., 2010). Lens placode invagination driven by Shroom3 is 
regulated by the lens-induction transcription factor Pax6 that activates Shroom3 
transcription in the surface ectoderm of the prospective lens (Plageman et al., 2010). A 
second regulator of Shroom3-mediated lens pit morphogenesis was later identified to be 
p120-catenin, which is required for Shroom3 localization to AJCs (Lang et al., 2014). 
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1.3.4.4 Thyroid Bud Morphogenesis   
Shroom3-induced apical constriction is also necessary in the morphogenesis of the 
thyroid bud, which is an outgrowth of the gut endoderm (Loebel et al., 2016). Formation 
of the thyroid bud critically depends on bending of the foregut endoderm, that bending 
depends on apical constriction. Knockout of Shroom3 in mouse embryos leads to ablation 
of apical constriction in the thyroid bud epithelium. Furthermore, knockout of the Rho 
GTPase protein Cdc42 has been shown to attenuate sub-cellular localization of Shroom3 
to the apical surface of thyroid bud epithelial cells. It is therefore proposed that Shroom3 
apical localization in the thyroid bud epithelium depends on concomitant Cdc42 
localization, in a manner similar to the RhoA-dependent localization of Shroom3 in the 
lens pit (Loebel et al., 2016).   
1.3.4.5 Gut Morphogenesis   
Shroom3 has also been shown to be critical for proper gut morphogenesis (Chung et al., 
2010; Grosse et al., 2011; Plageman et al., 2011). In Xenopus, the V-shaped morphology 
of the archenteron floor requires both apical constriction and apicobasal elongation, 
which are driven by Shroom3 (Chung et al., 2010). Regulation of Shroom3 in the 
developing gut is dependent on the transcription factor Pitx1, which directly activates 
Shroom3 transcription (Chung et al., 2010).  
Another role for Shroom3 in gut morphogenesis arose from the observation that 
Shroom3Gt/Gt mice mutants displayed abnormal gut rotation (Plageman et al., 2011). Gut 
rotation requires the establishment of asymmetry within the dorsal mesentery (DM) 
(Davis et al., 2008). This asymmetry is generated by the constriction and lengthening of 
gut epithelial cells mediated by Shroom3, resulting in leftward DM tilting. A second Pitx 
family member, Pitx2, together with the adhesion molecule N-cadherin, has been found 
to be involved in Shroom3’s activity within the DM, though Pitx2 in this case, unlike 
Pitx1 does not directly regulate Shroom3’s expression (Plageman et al., 2011).  
A third function for Shroom3 during later stages of gut morphogenesis was seen in the 
fetal intestinal epithelium of mice (Grosse et al., 2011). The increasing girth of the early 
intestinal epithelium during development appears to occur through the progressive 
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apicobasal elongation of epithelial cells in a pseudostratified manner, rather than through 
the addition of stratified cell layers as previously believed. Shroom3 has been found to be 
a vital determinant in the maintenance of a single-layered pseudostratified intestinal 
epithelium, with Shroom3Gt/Gt mice displaying aberrant organization of the apical 
actomyosin network, expanded apical surfaces, decreased cell height, and temporarily 
stratified intestinal epithelium (Grosse et al., 2011).  
1.4 Implications of Shroom3 in Disease  
1.4.1 Human SHROOM3 Variants  
While the developmental roles of Shroom3 have been supported by multiple studies in 
different models, an increasing amount of evidence for the role of Shroom3 in complex 
human diseases is emerging. The National Heart, Lung, and Blood Institute (NHLBI) has 
established an Exome Sequencing Project (ESP) in order to document the range of gene 
variants within the human population and to classify the variants as benign, possibly 
damaging, or probably damaging. The goal of the ESP was to identify novel candidate 
genes associated with heart, lung, and blood disorders through next-generation 
sequencing of protein coding regions. Genomes from over 200 000 individuals across a 
diverse range of phenotype-rich populations have been analyzed. Predictions about how 
damaging a variant could be were made using the computer program Polymorphism 
phenotyping version 2 (PolyPhen-2), which analyzes the effect of a single amino acid 
substitution on the function of the protein based on several phylogenetic, structural, and 
sequence features. Several variants in SHROOM3 have been predicted to be probably 
damaging by the NHLBI ESP (Table 1.3). Importantly, these variants could represent 
hypomorphic mutations with a phenotype analogous to Shroom3Gt/t mice, thus 
determining whether potentially damaging variants result in compromised Shroom3 
function is important in understanding whether these variants represent mutations that 
might increase susceptibility to disease.   
1.4.1.1 Heterotaxy 
In a separate study, one variant identified by the NHLBI has already been correlated with 
a rare but severe congenital heart disease (CHD) in humans known as heterotaxy (Tariq 
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et al., 2011). Heterotaxy is defined by the aberrant arrangement of internal thoraco-
abdominal organs caused by improper left-right (LR) patterning during development. The 
consequences of aberrant LR patterning are manifested as malformations in any of the 
organs asymmetric along the LR axis including the heart, spleen, and stomach (Kim, 
2011). Currently, the majority of genes known to cause heterotaxy in humans are 
members of the Nodal signaling pathway involved in LR patterning. However, the 
heterogeneity of heterotaxy phenotypes coupled with its sporadic pattern of inheritance 
have necessitated the need to identify additional gene candidates (Tariq et al., 2011).  
Using high-resolution SNP genotyping in combination with a whole-exome sequencing 
approach and homozygosity mapping, the authors identified several genetic variants in  
heterotaxy patients exhibiting multiple anomalies (Tariq et al., 2011). SHROOM3 was 
one of the variants identified and has a recessive missense mutation at amino acid 
position 60 with valine substituted for glycine. Interestingly, this substitution is within the 
PDZ domain of SHROOM3 indicating the need for further investigation of the PDZ 
domain with respect to Shroom3’s cellular function. Further analysis in 96 sporadic 
heterotaxy patients revealed two additional homozygous variants and two heterozygous 
variants. One of the heterozygous variants, which has a glycine to aspartic acid 
substitution at amino acid position 1864, is also one of the variants identified by the 
NHLBI and is predicted to be probably damaging by PolyPhen-2. Moreover, this variant 
is within a known domain location, ASD2, suggestive of impaired actomyosin 
contractility. Given that Shroom3 acts downstream of Pitx2 and N-cadherin to drive gut 
looping (see 1.3.4.5) and that ROCK2 has been found to be required for LR patterning in 
humans, the authors propose that the Pitx2-Shroom3-ROCK pathway could be a novel 
target for control of LR patterning. Functional analyses of the two aforementioned 
SHROOM3 variants will be a necessary next step in establishing a mechanistic link 
between SHROOM3 and heterotaxy.   
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Table 1.3 List of SHROOM3 variants predicted to be probably damaging by 
PolyPhen-2 in known domain locations. SNPs found within a diverse range of 
populations from over 200 000 individuals from the USA. The variant allele on the left 
represents the less common SNP and the variant allele on the right represents the most 
common SNP; alleles frequencies follow correspondingly.  *** denotes the homozygous 
G60V variant linked to the rare heterotaxy patient and ** denotes the heterozygous 
G1864D variant identified by (Tariq et al., 2011).  
 
Amino 
Acid 
Position 
Variant 
Allele 
Allele Frequency Amino 
Acid 
Change 
Protein 
Change 
Domain 
Location 
35 T/G T=1/G=13005 Val, Gly Missense PDZ 
60 C/G C=2/G=13004 Arg, Gly Missense PDZ 
60*** T/G T=34/G=12972 Gly, Val Missense PDZ 
80 T/A T=2/A=13004 Tyr, Asn Missense PDZ 
99 C/A C=1/A=13005 Ser, Tyr Missense PDZ 
106 C/G C=15/G=12991 Lys, Val Missense PDZ 
107 A/G A=2, G=13004 Arg, His Missense PDZ 
890 A/G A=1/G=12725 Asn, Ser Missense ASD1 
927 A/G A=1/G=12705 Asn, Ser Missense ASD1 
945 T/A T=1/A=12393 Val, Asp Missense ASD1 
1012 A/C A=67/C=12581 Asn, Thr Missense ASD1 
1058 A/G A=1/G=12979 His, Arg Missense ASD1 
1764 C/A C=2/A=13004 Gln, Lys Missense ASD2 
1778 C/G C=1/G=13005 His, Asp Missense ASD2 
1780 G/A G=1/A=13005 Ser, Asn Missense ASD2 
1812 C/A C=1/A=13005 Thr, Asn Missense ASD2 
1836 A/G A=1/G=13005 Ile, Met Missense ASD2 
1857 T/C T=1/C=13005 Cys, Arg Missense ASD2 
1857 A/G A=1/G=13005 His, Arg Missense ASD2 
1864** A/G A=7/G=12999 Asp, Gly Missense ASD2 
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1892 T/C T=1/G=13005 Trp, Arg Missense ASD2 
1892 A/G A=1/G=13005 Gln, Arg Missense ASD2 
1935 T/A T=1/A=13005 Lys, Gln Missense ASD2 
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1.4.1.2 Neural Tube Defects 
NTDs affect 6% of all births worldwide and are a substantial public health challenge due 
to their complex etiology of genetic and environmental interactions (Wallingford et al., 
2013). Folic acid supplementation in the diet of women who plan on conceiving has been 
widely endorsed as a preventative measure against NTDs (Pitkin, 2007). Several lines of 
evidence have shown the protective effects of folate against NTDs, specifically 
anencephaly, where exencephaly acts as the precursor, and spina bifida (Pitkin, 2007). 
Given Shroom3’s role in neural tube closure and the NTDs resulting from loss of 
Shroom3, it is predictive that folic acid supplementation would reverse the consequences 
of Shroom3 loss. However, in pregnant mice possessing an ENU-induced Shroom3 
mutation (Shroom3C5745T), long-term folic acid supplementation actually led to increased 
prenatal lethality in mutant embryos. The ENU-induced mutation (Shroom3C5745T) used in 
this study is a C to T transition in Exon 9 resulting in an arginine to cysteine substitution 
at amino acid position 1663; this mutation results in a hypomorphic allele. Interestingly, 
when the folic acid supplementation in the maternal diet was short-term, the effect was 
beneficial as evidenced by a significant decrease in mutant embryo lethality and a 
reduction in the prevalence of NTDs. These findings signify that the beneficial effects of 
FA supplementation, like NTDs themselves, are dependent on a number of factors 
including length of exposure to FA and the specific genetic background involved. It is not 
surprising that the complexity of NTDs and the multiple factors involved have resulted in 
the limited success of candidate gene studies in NTDs. Recently, de novo mutations 
(DNMs) have garnered increasing support as a common cause of birth defects and also 
explain why embryonically lethal diseases remain prevalent in the population (Veltman 
& Brunner, 2012). To identify potential candidate DNMs in novel genes associated with 
NTDs, exome data from 43 families consisting of one affected child and two unaffected 
parents with no other familial history of NTDs were analyzed. In two unrelated families, 
two loss-of-function heterozygous DNMs in SHROOM3 were identified. The first variant 
identified harbors C to G transition at nucleotide position 1176 resulting in a nonsense 
mutation; the mother of the affected child supplemented FA in her diet. The second 
variant carries a frameshift mutation inserting G at nucleotide position 2843, leading to a 
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premature stop codon; the mother of the affected child did not supplement FA in her diet; 
this mutation is located within the ASD1 domain (Lemay et al., 2015).  
Due to the linkage between heterotaxy and a recessive SHROOM3 mutation and the fact 
that neither of the affected patients exhibited heterotaxy, it is believed that the LoF 
DNMs may be acting in a haploinsufficient or dominant negative manner (Lemay et al., 
2015). Furthermore, the two affected children displayed different types of NTDs, with the 
first displaying anencephaly and craniofacial dysmorphism whereas the second displayed 
spina bifida (C1176G). Given that the more severe phenotype was associated with FA 
supplementation, and that long-term FA supplementation was found to be detrimental in 
the case of SHROOM3-related NTDs, it is possible that the mother was exposed to FA 
too long of a period. Irrespective of the role of FA in the maternal diet, this candidate 
gene study established, for the first time, a potential link between Shroom3’s role in 
neural tube closure and human NTDs (Lemay et al., 2015).  
1.4.2 Pulmonary Arterial Hypertension  
In addition to Shroom3’s association with congenital diseases due to its known roles in 
development, Shroom3 has been broadly implicated in adult disease. One of these 
diseases is pulmonary arterial hypertension (PAH), defined by a sustained elevation in 
pulmonary arterial pressure caused by injury to the pulmonary vasculature (Rubin, 2006). 
It is characterized by increased vascular proliferation and resistance leading to pulmonary 
vascular remodeling and decreased right ventricular function (Rubin, 2006). 
Histologically, it presents itself in lung tissue as intimal fibrosis, plexiform lesions, and 
increased medial thickness (Farber & Loscalzo, 2004). Of note, PAH is a separate disease 
from essential hypertension, which affects global blood pressure whereas PAH concerns 
only the blood pressure in the pulmonary arteries. Although the exact pathogenic 
mechanisms underlying PAH remain relatively uncharacterized, structural changes within 
the walls of the pulmonary arteries seem to play an essential role (Humbert et al., 2004). 
Similar to CKD, these changes are associated with ECM deposition and cell proliferation. 
Additionally, hypertrophy of pulmonary artery smooth muscle cells (PASMCs) caused by 
reorganization of the actin cytoskeleton has been strongly linked to PAH (Humbert et al., 
2004; Stenmark et al., 2006).  
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Shroom3 has been found to be expressed in the lungs of mice and humans, exclusively in 
PASMCs (Sevilla-Pérez et al., 2008). In the same study, hypoxia-induced PAH in mice 
and primary cultured PASMCs revealed downregulation of Shroom3. In humans with 
idiopathic PAH, Shroom3 expression was found to be attenuated in PASMCs when 
normalized to levels of smooth muscle actin-binding protein alpha-actin (Acta2). Thus, 
Shroom3 has been proposed to be a novel protein involved in PAH pathogenesis perhaps 
due to its role in maintaining the cytoskeletal architecture of PASMCs.  
1.4.3 HIV-Associated Neurocognitive Disorders (HAND) 
As highlighted in 1.3.4.3, Shroom3 has been shown to be involved in the adult CNS 
through inhibition of axon outgrowth. Recently, evidence of a potential role for Shroom3 
in the onset of adult neurodegenerative diseases has been found in a study looking at the 
molecular mechanisms involved in the onset of HIV-associated neurocognitive disorders 
(HAND) resulting from HIV infection in the CNS (Ganief et al., 2017). HAND affects 
70% of HIV-positive patients and encompasses a wide range of neuropathological 
disorders affecting cognitive, motor, and behavior functions (Antinori et al., 2007; Joska 
et al., 2011). Using proteomic analyses, SHROOM3 expression was found to be 
downregulated in neuroblastoma cells infected with HIV transactivator of transcription 
(HIV-Tat), an established inducer of neuronal damage. Several of the other proteins 
identified by the study also function as cytoskeletal regulators. The aforementioned study 
analyzed an extremely specific subset of neurodisorders, but given the known role of 
Shroom3 in regulating axon outgrowth, there is rationale for Shroom3 playing a role in 
the pathophysiology of common neurodisorders. Thus, although sparse, the evidence for 
Shroom3’s role in the onset of non-congenital diseases like pulmonary arterial 
hypertension and neural disorders is emerging.  
1.4.4 Chronic Kidney Disease    
The most significant evidence for Shroom3’s role in non-congenital disease comes from 
the multiple GWAS (see 1.2.6) that have identified SHROOM3 as having a strong 
correlation to CKD prevalence and incidence. These GWAS necessitated subsequent 
studies aimed at elucidating the role of Shroom3 in kidney function and disease.  
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Yeo et al. (2016) explored the role of Shroom3 function in the kidney using a zebrafish 
and rat model, namely the Fawn-Hooded Hypertensive (FHH) rat, which is an established 
hypertension and renal injury model. The FHH rat is a useful animal model in this 
experiment because Shroom3 is located within a quantitative trait loci (QTL) previously 
identified in the FHH rat and the FHH rat has 14 protein-coding variants of Shroom3 
compared to the wild-type allele. The central objective of this study was to determine 
whether or not spontaneous renal injury in the FHH rat is associated with altered 
Shroom3 function was a central objective.  
Introduction of a WT Shroom3 allele was found to significantly reduce the glomerular 
defects typically exhibited by the FHH rat. Specifically, introduction of WT Shroom3 
was found to result in lower levels of albuminuria, glomerulosclerosis, and foot process 
effacement. Subsequent analysis of the FHH Shroom3 allele revealed a variant within the 
ASD1 domain that disrupted binding to actin and could account for the FHH renal injury 
phenotype. These findings were further supported using zebrafish, in which Shroom3 is 
typically expressed in the pronephros during development. Global knockdown of 
Shroom3 using antisense morpholinos against Shroom3, was found to result in cardiac 
edema, a marker of pronephros dysfunction. Furthermore, RNA encoding the rat WT but 
not the FHH Shroom3 allele was able to rescue glomerular function in these zebrafish. 
When the knockdown of Shroom3 was specific to podocytes, achieved using a vector 
containing a dominant negative Shroom3 allele that ablates endogenous Shroom3 
function under the control of the podocyte-specific podocin promoter, zebrafish displayed 
foot process effacement and compromised GFB integrity (Yeo et al., 2015).  
Kidney transplantation is the best available treatment for CKD patients who progress to 
ESRD. In these patients, the most prevalent cause of renal transplant failure leading to 
dialysis or retransplantation is chronic allograft nephropathy (CAN) (Paul, 1999). CAN is 
characterized by a progressive loss of renal function in the allograft, with common 
histopathological markers including glomerulosclerosis and tubulointerstitial fibrosis 
(Chapman et al., 2005). The intronic SHROOM3 SNP rs17319271, identified by nearly 
all of the GWAS, has been implicated in the pathogenesis of tubulointerstitial fibrosis in 
CAN patients (Menon et al., 2015). This SNP has a G to A transition and presence of the 
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A allele in the donor but not the recipient correlated with decreased eGFR and increased 
allograft fibrosis in a prospective cohort of renal allograft recipients (GoCAR) at 12 
months post-transplantation. This decline in renal function was correlated to increased 
SHROOM3 expression in the allograft seen at 3 months post-transplant. Subsequent in 
vitro analyses of the SHROOM3 SNP revealed that the sequence containing the A allele 
functions as an enhancer element for the transcription factor 7-like-2 (TCF7L2). This 
enhancer element increases binding of β-catenin to the DNA complex of TCF7L2 and 
SHROOM3, activating SHROOM3 transcription. Downstream of the TCF7L2/β-catenin 
pathway, Shroom3 activity was found to be regulated by the transforming growth factor 
beta 1 (TGF-β1) (Menon et al., 2015). TGFβ1 is widely recognized as the primary 
pathological factor underlying fibrosis in CKD as it drives the expression of profibrotic 
genes. Importantly, when upregulated by TGF-β1, Shroom3 in turn, increases TGF-β1-
mediated profibrotic gene expression. Knockdown of Shroom3 resulted in decreased 
profibrotic gene expression in vitro in renal epithelial cells and decreased interstitial 
fibrosis in vivo in a murine kidney injury model (Menon et al., 2015).    
A study conducted by our lab and collaborators (Khalili et al., 2016), showed that 
Shroom3 is expressed in the developing kidney. Specifically, expression is found in the 
podocytes within the condensing mesenchyme, and in the medullary collecting ducts and 
podocytes of the adult kidney. The spatiotemporal expression of Shroom3 in the kidney 
was concomitant with a role for Shroom3 in glomerular development. Embryonic 
Shroom3Gt/Gt mice displayed aberrant glomerular morphology associated with the 
presence of cystic and collapsing glomeruli. At the ultrastructural level, these glomerular 
defects were characterized by abnormal podocyte morphology including foot process 
effacement attributed to abrogation of apical actin localization as well as loss of apical 
ROCK and myosin. The glomerular defects exhibited by Shroom3Gt/Gt mice were also 
observed in heterozygous Shroom3+/Gt mice.  
An important finding in the above study was that the glomerular defects in early 
nephrogenesis associated with Shroom3 deficiency resulted in a dose-dependent decrease 
in glomerular number at birth. Due to the fact that Shroom3Gt/Gt mice are embryonically 
lethal, Shroom3+/Gt mice were used to determine whether this reduced glomerular number 
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translated into decreased kidney function later in life. At one year of age, Shroom3+/Gt 
mice displayed significantly increased levels of proteinuria measured by UPCR as well as 
glomerulosclerosis and foot process effacement. Thus, Shroom3 appears to be a 
significant determinant in proper kidney development as well as kidney function in 
adulthood, specifically owing to its maintenance of podocyte architecture.  
Collectively, these studies have shed light on the role of Shroom3 in the kidney and have 
established functional support for the GWAS that have identified Shroom3 as a candidate 
gene for CKD. However, whether or not a deficiency in Shroom3 directly increases 
susceptibility to disease remains unclear.  
1.5 Hypertension and CKD: Re-visited  
While hypertension can cause CKD through a pathogenic mechanism involving 
progressive podocyte injury, the opposite is also true, as decreased kidney function can 
lead to increased systemic blood pressure. Hypertension is the leading global risk factor 
for mortality and affects more than 40% of adults worldwide, with this number projected 
to increase to 60% by 2025 (Kearney et al., 2005; World Health Organization, 2011) . 
Classification of blood pressure in adults is based on the average of BP measurements 
taken on two or more clinical visits (NHLBI, 2003). Hypertension is diagnosed on the 
basis of a systolic BP > 140 mm Hg and/or diastolic BP > 90mm Hg, with medical 
intervention beginning at the pre-hypertensive stage. Hypertension is the most frequent 
comorbidity of CKD, affecting 67-92% of patients (Center for Health Statistics, 2011).  
1.5.1 Hypertension Induced by Renal Dysfunction   
Nearly all cases of hypertension (90%) are of unknown cause, but there are a multitude of 
factors that clearly contribute to its pathogenesis (Oparil et al., 2003). Examples of 
pathophysiologic factors implicated in the onset of hypertension include long-term high 
sodium intake, deficiencies of vasodilators, overproduction of vasoconstrictors and 
sodium-retaining hormones, and increased sympathetic nervous system activity (Oparil et 
al., 2003). Collectively, these factors potentiate sustained elevation in blood pressure 
levels by increasing systemic vascular resistance and stiffness, as well as cardiac output 
(Foëx & Sear, 2004).   
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Table 1.4 Classification of hypertension. From the 7th Report of the Joint National 
Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure 
(JNC 7) (NHLBI, 2003).  
 
Blood Pressure 
Classification 
Systolic Blood Pressure  
(mm Hg) 
Diastolic Blood Pressure 
(mm Hg) 
Normal < 120  and < 80  
Pre-hypertension  120 – 139  or 80 – 89  
Stage 1 Hypertension  140 – 159 or 90 – 99  
Stage 2 Hypertension  >  160  or > 100  
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Kidneys play an essential role in blood pressure regulation through their function of 
sodium excretion. The importance of renal mechanisms in the pathophysiology of 
hypertension has been evidenced by several experimental and clinical hypertensive 
models, which have all been linked to a reduced ability of the kidneys to excrete sodium 
(Tedla et al., 2011). Excess sodium and water retention caused by renal injury leads to an 
increased production of vasoconstrictors such as angiotensin II, and a simultaneous 
decrease in the expression of vasodilators such as nitric oxide. The resulting imbalance 
towards the upregulation of vasoconstriction systems leads to an increase in renal 
vascular resistance, cardiac output, and consequently blood pressure (Oparil et al., 2003). 
1.5.2 Developmental Origins for Hypertension: The Brenner 
Hypothesis    
In 1988, Brenner put forth a hypothesis that nephron number and systemic blood pressure 
are inversely related based on his observation that hypertensive patients had reduced 
nephron number. The total number of nephrons present at birth or shortly after (as in the 
case of mice), is referred to as nephron endowment (Brenner et al., 1988; Didion, 2017). 
In contrast, the total number of nephrons measured at any given time post-birth is the 
nephron number (Didion, 2017). Due to the fact that nephrogenesis ceases at 36 weeks of 
gestation, nephron endowment represents the maximum amount of nephrons an 
individual can have in life with nephron number only declining afterwards. Glomerular 
number is used as an index for nephron number (Hoy et al. 2005). As mentioned in 
1.2.2.1, GFR is based on nephron number and the filtration rate within each individual 
nephron. When the GFR falls below a certain threshold, a pathological and progressive 
cycle of glomerular injury is initiated (Brenner and Mackenzie, 1997). The cycle begins 
with a reduction in nephron number and GFR that induces residual nephrons to 
compensate by increasing single-nephron GFR and glomerular surface area, resulting in 
high glomerular volume (Brenner et al., 1988). While this fulfills a compensatory 
function in the short-term, sustained glomerular hypertrophy and hyperfiltration result in 
increased fluid and sodium retention, increased extracellular fluid volume, and 
consequently contribute to the onset of hypertension (Brenner et al., 1988). Chronic 
hypertension then perpetuates glomerular injury by increasing renal blood flow and 
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glomerular capillary pressure leading to sclerosis, further nephron loss, and even higher 
blood pressure, perpetuating the cycle (Figure 1.6) (Didion, 2017). As explained in 
1.2.5.1, the degree of renal damage caused by hypertension-induced pathogenic 
mechanisms depends on local susceptibility factors, one of which includes glomerular 
hypertrophy. In individuals with reduced nephron endowment, glomerular hypertrophy 
then not only promotes hypertension but also increases the extent of kidney injury once 
hypertension develops.     
1.5.2.1 Determinants of Nephron Endowment  
Although the “average” number of nephrons per human kidney is approximately 1 
million, this is not a true representation of nephron number as the actual values range 
from 200 000 to 2.7 million (Bertram et al., 2011). The significant degree of variation 
reflects the diversity of factors that are involved in determining nephron number, 
including complex environmental and genetic factors (Gurusinghe et al., 2017). Birth 
weight has been recognized as a primary nephron number determinant. In humans, low 
birth weight attributed to intrauterine growth restriction or premature birth has been 
directly associated with reduced nephron endowment (Manalich et al., 2000). Genetics 
also play an important role, particularly those involved in regulating branching of the 
ureteric bud. Loss of fibroblast growth factor-7 (FGF-7), belonging to the FGF family of 
proteins, results in a 30% reduction in nephron number, abnormal renal papilla 
morphology, and smaller overall kidney size in mature FGF-7-null mice (Qiao, 1999).  In 
addition, environmental factors such as maternal diet have been found to play an 
important role (Gurusinghe et al., 2017).    
1.5.3 Regulation of Blood Pressure by the Kidney       
1.5.3.1 Renin-Angiotensin-Aldosterone System (RAAS)   
The kidneys play an essential role in regulating systemic blood pressure through a 
number of mechanisms. The renin-angiotensin-aldosterone system (RAAS) is one such 
established mechanism involved in the regulation of blood pressure and is a target for 
hypertension management (Weir and Dzau, 1999). Renin is secreted by renal 
juxtaglomerular cells in response to decreased blood pressure and converts  
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Figure 1.6 Progressive cycle of hypertension and CKD. Flowchart demonstrating the 
interdependence between kidney function and hypertension. Reduced nephron 
endowment due to factors such as low birth weight results in a lower nephron number. A 
lower nephron number leads to decreased GFR. When this decreased GFR falls below a 
threshold, the residual nephrons compensate by hyperfiltrating, leading to increased fluid 
and sodium retention and increased systemic BP. Increased systemic blood pressure then 
increases glomerular capillary pressure leading to hypertrophy and podocyte injury. 
Sustained increases in systemic BP result in irreversible podocyte injury that eventually 
manifests as glomerulosclerosis through cell-to cell-spreading. Glomerulosclerosis leads 
to further nephron loss and hyperfiltration in the residual glomeruli, exacerbating 
hypertension and perpetuating progressive renal dysfunction. Adapted from (Didion, 
2017). 
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angiotensinogen, secreted by the liver, into angiotensin I (Weir and Dzau, 1999). 
Angiotensin I is then converted into RAAS’ main effector Angiotensin II (AngII) by the 
angiotensin-converting enzyme (ACE), after which active AngII binds to Ang II type 1 
receptor sites in a variety of target tissues to exert its effects (Weir and Dzau, 1999). 
While under normal conditions, RAAS maintains water and sodium homeostasis and 
regulates tissue growth in the kidney, aberrant activation of RAAS leading to overactivity 
has been shown to be involved in the pathogenesis of both hypertension and CKD 
(Brewster and Perazella, 2004). Importantly, Ang II acts as a vasoconstrictor that 
promotes increases in blood pressure by elevating extracellular fluid volume and sodium 
reabsorption in the kidney (Weir and Dzau, 1999). Furthermore, AngII promotes fibrotic 
processes in the kidney by stimulating growth factors such as TGF-ß and FGF, inducing 
renal injury (Fogo, 2007).  
AngII also regulates renal hemodynamics and thus blood pressure through its action on 
the tubuloglomerular feedback system (Kobori et al., 2007). The tubuloglomerular 
feedback system regulates the GFR through the macula densa, which senses changes in 
the tubular fluid flow rate and NaCl concentrations and transmits signals to the 
juxtaglomerular cells in the afferent and efferent arterioles (Carroll, 2007). In this 
feedback system, the negative feedback signal is the delivery of NaCl to the distal tubule. 
A decrease in the NaCl concentration at the distal tubule is sensed by the macula densa, 
which causes the afferent arterioles to undergo vasodilation while simultaneous secretion 
of renin by the juxtaglomerular cells promotes vasoconstriction of the efferent arterioles 
(Carroll, 2007). Together, the actions of the arterioles increase glomerular capillary 
hydrostatic pressure and GFR, restoring the level of NaCl delivery to the distal tubule 
(Carroll, 2007). The sensitivity of the tubuloglomerular feedback system is enhanced by 
increased intrarenal AngII levels (Kobori et al, 2007). Augmented AngII levels increase 
proximal tubular reabsorption while decreasing NaCl delivery to the distal tubule, thereby 
decreasing urinary sodium excretion, and ultimately elevating extracellular fluid volume 
and blood pressure (Kobori et al., 2007). In the presence of an increased dietary sodium 
intake, salt excretion is further impaired, exacerbating elevations in blood pressure.    
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1.5.4 Sodium Intake and Hypertension      
Salt plays a central role in the development of hypertension and excess salt intake results 
in greater renal impairment of sodium excretion and exacerbation of hypertension. Long-
term blood pressure regulation critically depends on sodium and water balance. Impaired 
sodium excretion leads to increased water and sodium retention, which consequently 
elevates plasma volume and thus inevitably blood pressure (Blaustein et al., 2006). 
Sustained elevations in blood pressure then promote systemic hypertension through 
pressure natriuresis, as normal plasma volume is restored at the expense of increased 
blood pressure (Blaustein et al., 2006). Chronic hypertension can then potentiate further 
declines in kidney function through the pathogenic mechanisms discussed earlier. Rats 
placed on a high-salt diet exhibit significantly augmented levels of TGF-β in the kidneys, 
suggesting the promotion of pathways that lead to kidney fibrosis. Furthermore, salt-
restriction has been shown to have protective effects in uninephrectomized spontaneously 
hypertensive rats. After surgery, rats were placed on either a standard chow, low-sodium 
chow, or standard chow with sodium added to drinking water. All rats developed severe 
hypertension but 42 weeks after uninephrectomy, rats that were placed on the low-
sodium diet displayed significantly lower levels of proteinuria and glomerulosclerosis 
(Benstein et al., 1990) .  
In addition, a link between high-salt and the consequences of lower nephron endowment 
has been established. In a mouse model for reduced nephron number, mice were seen 
with 25% and 65% lower nephron counts compared to WT (Ruta et al., 2010). When 
placed on an acute 7-day 5% high-salt diet, mice with decreased nephron numbers 
showed greater increases in blood pressure and lower creatinine clearance in a dose-
dependent manner.    
High sodium diets are commonly used to study hypertension and renal injury in animal 
models that are not spontaneously hypertensive. They are particularly useful for assessing 
susceptibility to hypertension in heterozygous animals or homozygous mutants that are 
not embryonically lethal, in which the addition of an insult is needed to produce a 
phenotype. This is under the assumption that some form of underlying kidney stressor 
(i.e. reduced nephron endowment) provides the “first hit” increasing susceptibility to 
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external insults and the addition of a salt provides the “second hit,” thereby eliciting 
sustained injury (Ruta et al., 2010).  
1.6 Rationale, Hypotheses, Objectives   
1.6.1 Rationale 
Shroom3 has been shown to play a role in glomerular development and function, 
providing evidential support for the GWAS that have strongly associated Shroom3 with 
CKD. Importantly, even partial loss of Shroom3 in heterozygous Shroom3+/Gt mice, a 
model for hypomorphic Shroom3, was sufficient to produce glomerular defects in older 
mice. As I would not expect a complete loss of Shroom3 function in humans due to its 
requirement for neural tube closure, the observation that heterozygous Shroom3+/Gt mice 
exhibit compromised kidney function suggests that human SHROOM3 hypomorphs may 
be at risk for diseases dependent on the renal system. Hypertension is the most common 
comorbidity of CKD and is also a leading cause. This cause-and-effect relationship 
between the two diseases is attributed to a shared dependence on the glomerulus. The 
lower glomerular number coupled with abnormal podocyte morphology observed 
Shroom3+/Gt would suggest an increased susceptibility to hypertension. Furthermore, 
because hypertension induces kidney damage specifically through podocyte injury, 
podocytes with inherent structural defects should be more vulnerable to the mechanical 
and shear forces that accompany higher blood pressure. As a leading cause of CKD and 
as a significant risk factor for progression to ESRD and mortality, determining whether 
loss of Shroom3 predisposes individuals to hypertension will be important.  
The overarching goal of my project is to investigate how Shroom3 contributes to human 
health and disease by determining the potential consequences of altered Shroom3 activity 
using in vivo and in vitro models. 
1.6.2 Hypothesis and Objectives   
The hypothesis for my in vivo analysis is that partial loss of Shroom3 activity increases 
susceptibility to CKD. I will address this hypothesis through the following objectives:  
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1) Determine if Shroom3+/Gt mice are more susceptible to hypertension  
 
2) Determine if a high-salt diet exacerbates renal injury in Shroom3+/Gt mice   
 
For my in vitro analysis, I hypothesize that potentially damaging SHROOM3 variants 
identified by the NHLBI with mutations in known domain locations will have 
compromised Shroom3 function. I will address this through the following objective:  
 
3) Examine the ability of potentially damaging SHROOM3 variants to induce apical 
constriction in cultured epithelial cells 
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Chapter 2  
2 Materials and Methods  
2.1 Mice 
All mice used in this study were bred from the Shroom3 gene trap line (B6.129S4-
Shroom3Gt(ROSA53)Sor/J) purchased from the Jackson Laboratory. The mice are 
derived from the original line generated by Hildebrand and Soriano (1999). The line 
was bred onto the C57BL/6 background and is considered congenic with that strain. 
The gene trap mutation inserted an adenovirus splice acceptor (Friedrich & Soriano, 
1991), a bifunctional gene fusion between β-galactosidase and Cre recombinase, and 
the MC1 polyadenylation (pA) sequence. This results in elimination of the short 
isoform and a severe truncation of the long isoform of Shroom3. Due to the 
embryonic lethality of homozygous Shroom3 mutants, the line is maintained using 
Shroom3 gene trap mice only carrying one copy of the gene trap allele (Shroom3+/Gt). 
All mice were housed in an animal care facility and maintained on standard rodent 
chow prior to the experimental period. All studies were approved by the University of 
Western Ontario’s Animal Care Committee (Protocol #: 2015-026) and were in 
accordance with the guidelines of the Canadian Council on Animal Care (CCAC). 
2.2 Genotyping  
The genotypes of all mice were analyzed by PCR using primers specific for the 
Shroom3 gene-trap allele. DNA was extracted from the ear clips of 21 day-old pups 
and immediately lysed in tissue lysis buffer (100mM Tris-Cl pH 8.5, 5mM EDTA pH 
8.0, 200mM NaCl, 0.2% SDS (w/v) in dH2O) containing 100μg/mL of Proteinase K 
overnight at 55°C. The following day, phenol/chloroform extraction was used to 
separate the remaining protein from the DNA samples. The samples were subjected to 
PCR for 30 cycles of the following parameters: 95°C for 45 seconds, 60°C for 45 
seconds, and 72°C for 45 seconds. The sequences of the primers: a forward primer 5’- 
GGTGACTGAGGAGTAGAGTCC -3’ (F11) and a reverse primer R1 (5’- 
GAGTTTGTGCTCAACCGCGAGC -3’ (R1) amplified the Shroom3 gene trap 
allele. To detect the wild-type Shroom3 allele, the forward primer (F11) was paired 
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with the reverse primer R4 (5’- GCAACCACATGGTGGGAGACAAGC -3’). The 
expected amplicon size of the gene-trap allele was 1500 bp and only mice that were 
heterozygous were expected to display a band. The expected amplicon size for the 
wild-type allele was 1000 bp and both heterozygous and wild-type mice were 
expected to display a band.  
2.3 High-Salt Model  
Congenic WT (C57BL/6) and Shroom3+/Gt male mice were bred and raised on 
standard rodent chow prior to the experimental period. Only male mice were 
considered for this study as female mice are more resistant to developing 
hypertension (Hyndman and Pannabecker, 2015). Animals were randomly assigned to 
either a normal salt diet continuing with the same standard rodent chow (NS) or a 
high-salt diet (HS) consisting of 8% NaCl with 1% NaCl in drinking water. Mice 
were able to freely access food and water at all times. The experimental groups were 
as follows: wild-type mice on NS, wild-type mice on HS, Shroom3+/Gt mice on NS, 
and Shroom3+/Gt mice on HS. Both the normal salt diet (cat. no. 2019) and high-salt 
diet (cat. no. TD92012) were purchased from Harland Teklad (Madison, WI, U.S.A). 
The high-salt diet groups were initiated on the diet after basal level systolic blood 
pressure was measured; normal salt diet groups remained on the standard chow for 
the duration of the basal and experimental periods. Mice were between the ages of 5-
7 months at the start of the experimental period. Studies were conducted in three 
sequential rounds, and data from each round was pooled for each experimental group.  
2.4 Blood Pressure Measurements (Tail-Cuff) 
Blood pressures of conscious mice were measured using a CODA 6-Channel High 
Throughput Non-Invasive Blood Pressure system (CODA-HT6, Kent Scientific, 
Torrington, CT, USA) according to the manufacturer’s instructions. The apparatus 
applies the tail-cuff method to determine blood pressure. Mice were placed into 
holders that restrained movement; the head was secured with a nose cone while the 
tail extended out of the rear end of the holder. The holders were kept on a warming 
platform to maintain the mice at a minimum temperature of 32C for the duration of 
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the experiment. Two cuffs were placed around the tail: an occlusion cuff which 
impedes blood flow by inflation, and a Volume Pressure Recording (VPR) cuff which 
measures the swelling of the tail that occurs as a result of returning blood flow upon 
deflation of the occlusion cuff. The VPR sensor measures and outputs six different 
physiological readings: systolic and diastolic blood pressure, mean arterial pressure, 
heart rate, tail blood flow, and tail blood volume. In order to condition the mice and 
minimize the level of stress caused by the tail-cuff apparatus, mice were trained on a 
daily basis for 2-3 weeks prior to taking the basal blood pressure measurement. Blood 
pressures were monitored over two sets of 15 cycles each, with 5 additional 
acclimatization cycles at the start of the first set; measurements were taken at the 
same time each day.   
2.5 Tissue Collection  
At the end of each experimental period, mice were weighed then euthanized by CO2. 
The heart was extracted, trimmed of excess cardiac and atrial tissue, and washed in 
ice-cold 1xPBS. Hearts were blotted dry and weighed on the same scale used to 
measure body weight, and heart weight to body weight ratios were calculated. In 
addition, the kidneys were dissected out, cut longitudinally, and rinsed in ice-cold 1x 
PBS. Kidneys were then fixed for at least 24 hours at 4C in either 4% PFA or 10% 
formalin. Samples were then transferred to tissue cassettes and sent to our 
collaborators at University Hospital (London, ON) to be dehydrated, embedded in 
paraffin, and subsequently sectioned. Sections were cut at a thickness of 4μm and 
stained with hematoxylin and eosin to visualize tubules and glomeruli, and with 
Masson’s Trichome to visualize interstitial fibrosis. All slides were visualized using a 
Leica DM5500 B microscope (cat. no. 380492, Leica Camera AG, Wetzlar, 
Germany).  
2.6 Urinalysis   
Urine was collected on various days during the course of the diet treatment; collection 
always occurred at the same time each day (9 am). To induce urination, the mouse 
was scruffed and pressure was directly applied to the bladder area. The urine was 
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collected on a piece of Parafilm® M then transferred to an Eppendorf tube and stored 
at -80C until ready for analyses. Urine was analyzed for urinary protein and 
creatinine levels (University Hospital, London, ON, Canada).  
2.7 Generation of SHROOM3 Variants   
The substitution mutations corresponding to the human Shroom3 variants of interest 
were introduced into the full-length Shroom3 construct using a Quikchange II XL 
Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA, USA) 
according to the manufacturer’s instructions. PCR amplification of oligonucleotide 
primers containing the desired substitution was used to generate mutated plasmids 
(see Table 2.1 for primer sequences). The resulting PCR products were digested with 
a Dpn I treated endonuclease to digest the parental DNA template and to select for 
newly synthesized DNA carrying the desired mutation.  
The mutated DNA generated by PCR amplification was transformed into XL10-Gold 
Ultracompetent cells (Agilent Technologies, Santa Clara, CA, USA) and plated on 
LB-ampicillin agar plates. The following day, colonies were selected from the plates 
and inoculated in LB broth overnight at 37C. Plasmid DNA was then isolated from 
the bacterial inoculates using a standard plasmid miniprep kit (Qiagen, Valencia, CA, 
USA). To confirm that the plasmid DNA was carrying the mutation of interest, all 
plasmid DNA samples were sequenced at Robarts Research Institute (University of 
Western Ontario, London, ON, Canada).  
2.8 Cell Culture and Transfection  
The Madin-Darby canine kidney (MDCK) epithelial cell line was obtained from  
ATCC (Manassas, VA, USA). Importantly,  this cell line is epithelial rather than 
mesenchymal and has been used for apical constriction assays by several previous 
studies that have looked at Shroom3 function; the cells do not endogenously express 
SHROOM3 (Dietz et al., 2006; Hildebrand, 2005; Plageman et al., 2011). The cell 
line was maintained in DMEM (Thermo Fisher Scientific, Waltham, MA, USA) 
supplemented with 10% FBS and grown in 55 cm2 petri dishes at 37C, in a  
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Table 2.1 Primer sequences for PCR used to generate SHROOM3 variants 
 
Variant Forward Primer (5’ to 3’)  Reverse Primer (5’ to 3’) 
G60V TCTAAGGTCGAAGAAGTGGG
CAAAGCAGACACC 
GGTGTCTGCTTTGCCCACTTCTTCGACC
TTAGA 
T1012N  CTCGCCGGCGCCTGAATCCCG
AGC 
GCTCGGGATTCAGGCGCCGGCGAG 
G1864D GAGAATGTCCTTAGCGACCTT
GGTGAAGATGC 
GGCATCTTCACCAAGGTCGCTAAGGAC
ATTCTC 
 
  
58 
 
humidified 5% CO2 incubator. Cells were passaged every other day until they reached 
70% confluency and appeared to be cobblestone-like in shape and structure. Cells 
were seeded on glass coverslips in a 6-well plate at a density of 0.5-1 x 107 cells/mL 
one day before transfection and grown to 80-90% confluency prior to transfection. 
One hour prior to cell seeding, fibronectin (Sigma-Aldrich, St. Louis, MI, USA) was 
added to each glass coverslip at a 1:750 dilution in 1x PBS to enhance cellular 
adhesion. To transfect cells, the DMEM + 10% FBS that the cells were plated in was 
first aspirated from each of the six wells and replaced with pre-warmed Opti-MEM 
reduced serum medium (Invitrogen, Carlsbad, CA, USA). All transfections were 
carried out using the plasmid vector pEF-I-GFP-GX (Plasmid #45443, Addgene, 
Cambridge, MA, USA) that contains an internal ribosome entry site (IRES) that 
allowed for bicistronic expression of both GFP and SHROOM3 from a single 
transcript while circumventing the potential disruption of function that could arise 
from the production of a GFP fusion protein. All transfections were carried out with 
the inclusion of a negative control, an empty GFP plasmid vector, and a positive 
control, a vector harboring WT SHROOM3.   
 
Cells were transfected using the transfection agent Lipofectamine 3000, according to 
the manufacturer’s protocol (Invitrogen). Two sets of solutions were prepared in 
separate tubes for transfection. The first set contained 7.5 µl of Lipofectamine 3000 
diluted in 125 µl of Opti-MEM. The second set contained 2µg of plasmid DNA 
diluted in 125 µl of Opti-MEM with 4 µl of P3000 Enhancer Reagent (Invitrogen). 
An equal 1:1 ratio of each solution (125 µL each) was pooled together and incubated 
for 5 minutes at room temperature to allow proper lipoplex formation. The complex 
was then added to each of the wells containing cells and Opti-MEM, and the plate 
was incubated at 37C for 48 hours.  
2.9 Immunofluroescence   
Cells were washed three times in 1x PBS 48 hours post-transfection and subsequently 
fixed in 4% PFA for 15 minutes at room temperature. After, cells were washed three 
more times in 1x PBS and permeabilized in 0.2% Triton-X100 diluted in PBS for 5 
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minutes at room temperature. Cells were then left in 0.1% Tween 20 diluted in 1x 
PBS for 30 minutes at room temperature to allow blocking. The blocking buffer was 
removed and cells were incubated with the mouse anti ZO-1 monoclonal antibody 
(ZO1-1A12) conjugated to Alexa Fluor 594 for 1 hour at room temperature to enable 
visualization of intercellular boundaries (cat. no. 339194, 1:100, Thermo Fisher 
Scientific, Waltham, MA, USA). ZO-1 is a tight junction protein that can be stained 
to outline apical cell-cell boundaries. Cells were washed three times in 1x PBS then 
counterstained with DAPI (1:1000 in 1x PBS) for 7 minutes at room temperature. 
After a final three washes, slides were mounted with PermaFluor Aqueous Mounting 
Medium (Thermo Fisher Scientific) and stored at 4C. All slides were visualized by 
fluorescence microscopy using a Leica DM5500 B microscope.  
All microscope images were analyzed using ImageJ software (National Institutes of 
Health, Bethesda, MD, USA). To quantify apical constriction, cell profiles were 
traced and measured using ImageJ similar to previously described methods (Das et 
al., 2014; Plageman et al., 2010). The apical area was defined as the area of the cell 
outlined by red ZO-1 staining. Between 22 – 25 randomly picked cells from 2 – 4 
independent experiments were analyzed (see Appendix F).   
2.10 Statistical Analysis  
All statistical analysis was performed using GraphPad Prism 7 (GraphPad Software 
Inc., San Diego, CA, USA). For physiological measurements, statistical analysis 
between genotypes at baseline was conducted using an unpaired Student’s t-test. 
Differences between experimental groups during the dietary treatment period were 
analyzed using two-way ANOVA, followed by a Tukey’s post-hoc test. A one-way 
ANOVA with repeated measures followed by a Dunnett’s multiple comparisons test 
was used to determine statistical significance within experimental groups; three 
individual mice were omitted from analysis (see Appendix A). For apical constriction 
assays, statistical differences between controls and variants were analyzed using one-
way ANOVA followed by a Dunnett’s multiple comparison test while statistical 
differences between transfected cells and neighboring cells were analyzed by an 
unpaired t-test. P-values < 0.05 were considered statistically significant.   
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Chapter 3  
3 Results   
3.1 Physiological effects of Shroom3 loss  
Previous work in our lab has revealed that loss of Shroom3 is associated with glomerular 
defects during development that result in compromised renal function later in adulthood 
(Khalili et al., 2016). Importantly, the reduced glomerular number found in Shroom3+/Gt 
mice, would suggest an increased risk for developing adult onset hypertension. To 
determine whether loss of Shroom3 increases susceptibility to hypertension, congenic 
wild type (WT; Shroom3+/+) and heterozygous Shroom3+/Gt mice were treated with either 
a high-salt (HS) diet or normal-salt (NS) diet for four weeks. Initially, a HS diet 
consisting of 4% NaCl in chow was chosen for my study. However, this diet was not 
sufficient to produce any observable changes in blood pressure in any of the four mice 
cohorts (data not shown). A more commonly used diet to generate high blood pressure in 
experimental models is the 8% NaCl diet (Bohlooly et al., 2001; Mathis et al., 2011; 
Nakagawa et al., 2006; Obih & Oyekan, 2008; Oliver et al., 1997; Watanabe et al., 2005; 
Yu et al., 2004), sometimes supplemented with 1% NaCl in drinking water (Brochu et al., 
2002; Greenwald et al., 1988; Hernandez et al., 2015; Ofem et al., 2014). As such, I 
treated mice with either 8% NaCl in chow with 1% NaCl in drinking water or standard 
chow over a period of four weeks and assessed six different physiological parameters 
using the CODA 6-Channel High Throughput Non-Invasive Blood Pressure system. 
Weeks 1, 2, 3 and 4 correspond to measurements taken on days 7, 14, 21, and 28 of 
treatment, respectively. However, when mice exhibited signs of high-stress on any given 
day, including resistance to being placed in the holders or frequent movement while 
measurements were being taken, blood pressure measurements were taken the next day.  
To determine whether loss of Shroom3 has physiological effects under basal conditions, 
baseline measurements of body weight, heart rate, and blood pressure for 5-7 month old 
congenic male WT and Shroom3+/Gt mice were analyzed. Baseline values were calculated 
by averaging recordings obtained from at least two different days during the week 
preceding the first day of treatment. There was no significant difference in body weight, 
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heart rate (HR), diastolic blood pressure (DBP), mean arterial blood pressure (MAP), or 
systolic blood pressure (SBP) between WT and Shroom3+/Gt mice at baseline (Figure 3.1). 
These results suggest that loss of Shroom3 does not have physiological consequences 
under normal conditions at 5-7 months of age.    
3.1.1 Body weight and heart rate  
Upon treatment with a high-salt diet, no significant differences in body weight were seen 
between the experimental groups at any of the weekly time points throughout the four-
week period (Figure 3.2). WT and Shroom3+/Gt mice on a normal-salt diet generally 
appeared heavier than mice on a HS diet, however, this was not statistically significant 
(Figure 3.2A, C). Surprisingly, both WT and Shroom3+/Gt  mice on a NS diet were found 
to be significantly heavier at four weeks compared to the baseline (WT p=0.0079, 
Shroom3+/Gt p = 0.0343; Figure 3.2E). This unexpected finding may be explained, at least 
in part for the WT mice, by one of the mice from the cohort gaining a substantial amount 
of weight near the last two weeks of the experimental period; this mouse was also found 
with extremely high blood pressure by week 4 (see Appendix B). There was no 
significant difference found within either of the two HS experimental groups throughout 
the duration of the treatment period. 
There were no significant differences seen in heart rate between the four experimental 
groups at any of the weekly time points during the dietary period (Figure 3.3). In 
addition, no significant changes in heart rate were seen within the experimental groups 
during the four-week period when compared to baseline measurements.     
3.1.2 Blood Pressure  
Diastolic blood pressure (DBP), defined as the minimum blood pressure recorded when 
the heart is at rest between contractions, systolic blood pressure (SBP) defined as the 
maximum blood pressure recorded when the heart contracts, and mean arterial pressure 
(MAP), which is calculated using the DBP and SBP, were assessed to determine the 
effects of Shroom3 loss in the presence of a high-salt diet (Brzezinski, 1990).  
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Figure 3.1 Comparison of baseline physiological parameters between WT and 
Shroom3+/Gt mice.  Measurements for body weight (A), heart rate (B), diastolic blood 
pressure (C), mean arterial pressure (D), and systolic blood pressure (E), taken prior to 
the dietary period are shown. Individual dots represent the average of measurements 
taken from 2 or 3 different days in the week prior to the start of the NS or HS diet. Mice 
were trained for use of the tail-cuff system for a minimum of 2 weeks before recording 
baseline measurements. Data expressed as mean ± SEM; n = 27 for WT, n=17 for 
Shroom3+/Gt mice for all panels with the exception of body weight (n=17 for WT, n=11 
for Shroom3+/Gt mice; body weight was not measured in the first independent 
experiment). 
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Figure 3.2 Effects of high-salt diet and Shroom3 loss on body weight. Time-course of 
body weight of WT and Shroom3+/Gt mice on a NS (C) and HS (D) diet. A summary of 
all four groups is shown in (E). The data was grouped in multiple ways to depict the 
comparison between diet as well as genotype. Data expressed as mean ± SEM; n= 4-8 for 
NS groups and n= 7-10 for HS groups. (# p < 0.05 vs. baseline, repeated measures one-
way ANOVA with Dunnett’s multiple comparisons test).  
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Figure 3.3 Effects of high-salt diet and Shroom3 loss on heart rate. Time-course of 
HR from baseline (week 0) to the end of the treatment period (week 4) for WT (A) and 
Shroom3+/Gt (B) mice on a NS and HS diet, as well as WT and Shroom3+/Gt mice on a NS 
(C) and HS (D) diet. Measurements were taken 7, 14, 21, and 28 days after the start of the 
dietary period using the tail-cuff blood pressure system. A summary of all four groups is 
shown in (E). No significant differences were found between groups (two-way ANOVA 
with Tukey’s post-hoc) or within groups (repeated measures one-way ANOVA with 
Dunnett’s multiple comparison test). Data expressed as mean ± SEM; n= 7-11 for NS 
groups and n= 9-16 for HS groups.   
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Increased dietary salt intake did not lead to a significant difference in the DBP (Figure 
3.4) or MAP (Figure 3.5) of WT mice compared to WT mice on a normal salt diet. 
However, when Shroom3+/Gt mice were placed on a HS diet, they exhibited a significant 
decrease in DBP compared to Shroom3+/Gt on a NS diet at week 2 (p=0.0129) and 3 
(p=0.0319) and WT mice on a NS diet at week 2 (p=0.0140) of the treatment period 
(Figure 3.4B). Shroom3+/Gt mice on a HS diet also displayed significantly decreased MAP 
at weeks 2 (p=0.0108) and 3 (0.0388) compared to Shroom3+/Gt mice on a normal salt diet 
(Figure 3.5B). Generally, increased sodium intake led to a decrease in DBP and MAP for 
both WT and Shroom3+/Gt mice, but this difference was significantly greater in 
Shroom3+/Gt mice at weeks 2 and 3 compared to WT mice, suggesting that when 
challenged with a HS diet, loss of Shroom3 may lead to decreased ability to regulate 
blood pressure. No significant differences were seen within the experimental groups 
when compared to baseline measurements.  
SBP is believed to be a more important predictor of cardiovascular risk than DBP, with 
many studies suggesting that SBP should be the primary focus of antihypertensive 
therapy (Kannel, 2000; Leonetti et al., 2000; Wilkinson & Cockcroft, 2000). SBP is also 
considered the most useful and accurate cardiac parameter measured by the tail-cuff 
technique (Feng et al., 2008). Therefore, the majority of my blood pressure data will 
primarily focus on SBP. As expected, no significant differences in SBP levels were 
observed between WT and Shroom3+/Gt mice on a NS diet over the four-week period 
(Figure 3.6A). Surprisingly, a HS diet did not cause a significant increase in the SBP of 
Shroom3+/Gt mice over the course of the treatment period compared to baseline SBP 
levels (Figure 3.6B). However, interestingly, Shroom3+/Gt mice on a NS diet had 
significantly higher SBP at week 3 compared to the baseline level (Figure 3.6B). Similar 
to DBP and MAP findings, a HS diet appeared to cause lower SBP levels compared to a 
NS diet in both Shroom3+/Gt mice and WT mice, with a greater difference seen in 
Shroom3+/Gt mice compared to WT mice, although not statistically significant. The 
finding that a HS diet does not lead to an increase in blood pressure levels in WT mice is 
consistent with previous studies that have used a 8% HS model (Bao et al., 2014; 
Daumerie et al., 2010; Davenport et al., 2015; Iida et al., 2005; Ye et al., 2006).  
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Figure 3.4 Effects of high-salt diet and Shroom3 loss on diastolic blood pressure. 
Time-course of DBP from baseline (week 0) to the end of the treatment period (week 4) 
for WT (A) and Shroom3+/Gt (B) mice on a NS and HS diet, as well as a time-course of 
DBP of WT and Shroom3+/Gt mice on a NS (C) and HS (D) diet. Measurements were 
taken 7, 14, 21, and 28 days after the start of the dietary period using the tail-cuff blood 
pressure system. A summary of all four groups is shown in (E). DBP was significantly 
lower in Shroom3+/Gt mice on a HS diet compared to WT and Shroom3+/Gt mice on a NS 
diet (*p <0.05 vs. Shroom3+/Gt mice, ^p < 0.05 versus WT mice). Data expressed as mean 
± SD; n= 7-11 for NS groups and n= 9-16 for HS groups.   
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Figure 3.5 Effects of high-salt diet and Shroom3 loss on mean arterial pressure. 
Time-course of MAP from baseline (week 0) to the end of the treatment period (week 4) 
for WT (A) and Shroom3+/Gt (B) mice on a NS and HS diet, as well as a time-course of 
MAP of WT and Shroom3+/Gt mice on a NS (C) and HS (D) diet. Measurements were 
taken 7, 14, 21, and 28 days after the start of the dietary period using the tail-cuff blood 
pressure system. A summary of all four groups is shown in (E). MAP was significantly 
higher in Shroom3+/Gt mice on a HS diet compared to Shroom3+/Gt mice on a NS diet (*p 
< 0.05 two-way ANOVA with Tukey’s post-hoc test). Data expressed as mean ± SD; n= 
7-11 for NS groups and n= 9-16 for HS groups.  
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Figure 3.6 Effects of high-salt diet and Shroom3 loss on systolic blood pressure. 
Time-course of SBP from baseline (week 0) to the end of the treatment period (week 4) 
for WT (A) and Shroom3+/Gt (B) mice on a NS and HS diet, as well as a time-course of 
SBP of WT and Shroom3+/Gt mice on a NS (C) and HS (D) diet. Measurements were 
taken 7, 14, 21, and 28 days after the start of the dietary period using the tail-cuff blood 
pressure system. A summary of all four groups is shown in (E). SBP was significantly 
higher in Shroom3+/Gt mice on a NS diet at week 3 in comparison to the baseline. (# p < 
0.05 versus baseline). Data expressed as mean ± SD; n= 7-11 for NS groups and n= 9-16 
for HS groups.   
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Surprisingly, however, results thus far would suggest that a HS diet does not induce 
elevations in blood pressure in Shroom3+/Gt mice, but may rather lead to decreased blood 
pressure levels.  
3.1.3 High-salt diet increases blood pressure variability in 
Shroom3+/Gt mice   
A closer look at the SBP trends of Shroom3+/Gt mice on a HS diet may at least in part 
explain the unexpected SBP findings that a HS diet leads to a decrease in blood pressure. 
Throughout the period of high-salt treatment, I noticed that the SBP of Shroom3+/Gt mice 
on a high-salt diet varied considerably over time and between individual mice (see 
Appendix B). Specifically, some mice consistently exhibited noticeable increases in SBP, 
while others exhibited a consistent decrease, and yet some mice exhibited both an 
increase and decrease over the course of the high-salt diet, leading to a large range in 
SBP values in Shroom3+/Gt mice on a HS diet compared to the baseline range (Figure 
3.7A). Moreover, the variance of Shroom3+/Gt mice was significantly higher than the 
variance of WT mice at week 1 and 3 of salt loading, as determined by the F-test for 
equality of variances (week 1 p=0.0254, week 3 p=0.0001; Figure 3.7B, D).  
To assess the degree of change in blood pressure and to determine whether such changes 
were significantly different between experimental groups, I compared the change in SBP 
from the baseline level for each week of the treatment period. An absolute value for 
change was used to account for both increases and decreases in blood pressure over time, 
as a large negative and a large positive value would cancel each other out and reflect 
minimal change, and I was interested in the magnitude of change rather than the 
direction. As shown in Figure 3.8, Shroom3+/Gt mice showed significantly higher changes 
in SBP compared to WT mice at all four weekly time points during the HS diet (week 1 
p=0.0133, week 2 p=0.0029, week 3 p=0.0459, week 4 p=0.0460). Shroom3+/Gt mice on a 
HS diet also had significantly higher changes in SBP compared to Shroom3+/Gt mice on a 
NS diet in the first two weeks of the HS diet (week 1 p=0.0345, week 2 p=0.0136) and 
compared to WT mice on a NS diet in the last three weeks of the HS diet (week 2 
p=0.0054, week 3 p=0.0024, week 4 p=0.0203). No significant differences between the  
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Figure 3.7 A high-salt diet increases SBP variance in Shroom3+/Gt mice. Box plots 
depicting the range in SBP values (A) and interleaved scatter plots depicting the high 
variability in SBP values in HS Shroom3+/Gt mice at week 1 (A), 2 (B), 3 (C), and 4 (D), 
of the dietary period. On a HS diet, Shroom3+/Gt mice exhibit a significant increase in 
variance in SBP measurements compared to WT mice (**p=0.0254, ***p=0.0001, F-test 
to compare equality of variances). Data expressed as mean ± SD; n= 7-11 for NS groups 
and n= 9-16 for HS groups.  
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Figure 3.8 Absolute change in systolic blood pressure in response to a high-salt diet. 
SBP measurements at one week (A), two weeks (B), three weeks (C), and four weeks (D) 
after the start of the dietary treatment period were subtracted from baseline SBP values. 
Delta SBP reflects an absolute value; negative delta values were considered to be positive 
in calculations as I was only interested in the magnitude of change not the direction, due 
to mice reflecting both increases and decreases in SBP throughout the treatment period. A 
high-salt diet caused a greater change in SBP from baseline in Shroom3+/Gt mice 
compared to WT mice and Shroom3+/Gt mice on a NS diet and WT mice on a HS diet (*p 
< 0.05, **p < 0.01, two-way ANOVA with Tukey‘s post-hoc test). Data expressed as 
mean ± SD; n= 7-11 for NS groups and n= 9-16 for HS groups.   
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other experimental groups were observed, suggesting that a HS diet induces greater 
fluctuations in blood pressure in Shroom3+/Gt mice in a manner dependent on loss of 
Shroom3.   
The high SBP variance observed in Shroom3+/Gt mice on a HS diet is reflected by the 
high standard deviation within this group, an outcome of the discrepancy in the 
directional change in blood pressure, with mice exhibiting both increases and/or 
decreases. For this reason, the SBP data was expressed as mean ± SD rather than SEM to 
depict variability. Both long-term and short-term blood pressure variability (BPV) are 
associated with cardiovascular and renal disease outcomes as well as all-cause mortality 
in humans (Mancia, 2012). The SD of the mean SBP calculated from sequential blood 
pressure measurements is an established index for BPV (Dolan & O’Brien, 2010; Kikuya 
et al., 2008; Rothwell et al., 2010; Stevens et al., 2016). A previous study that assessed 
day-to-day variability of blood pressure and heart rate as a novel predictor of 
cardiovascular mortality in humans proposed that at least 10 blood pressure 
measurements taken on 10 different days are necessary to provide a reliable SD of blood 
pressure (Kikuya et al., 2008). Therefore, the SD of blood pressure measurements taken 
on various days throughout the four-week dietary period was calculated; 11 different 
blood pressure measurements were used in total (see Appendix C). A HS diet 
significantly elevated BPV in both WT and Shroom3+/Gt mice compared to WT mice on a 
NS diet (WT p=0.0482, Shroom3+/Gt p<0.0001; Figure 3.9). However, this increase in 
BPV associated with a HS diet was significantly higher in Shroom3+/Gt mice compared to 
WT mice (p<0.0001). Furthermore, Shroom3+/Gt mice also had significantly higher BPV 
compared to Shroom3+/Gt mice on a NS diet, indicating that this increase in BPV was 
dependent on increased dietary sodium (p<0.0001). These results strongly suggest that 
loss of Shroom3 is associated with alterations in blood pressure leading to greater blood 
pressure variability in the presence of a sodium insult.    
3.2 A short-term high-salt diet does not promote renal injury 
in Shroom3+/Gt mice  
High dietary sodium plays a central role in the pathophysiology of chronic kidney 
disease. In order to determine whether a high-salt diet promotes renal injury in Shroom3  
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Figure 3.9 Loss of Shroom3 leads to elevated blood pressure variability on a high-
salt diet. The standard deviation of SBP is an established index of blood pressure 
variability. SD was calculated from the average SBP value of measurements taken at 
week 1, 2, 3, and 4 of the dietary treatment period. When placed on a HS diet, WT and 
Shroom3+/Gt mice exhibit significantly higher blood pressure variability compared to WT 
mice on a NS diet, but this increase in BPV caused by the HS diet is significantly higher 
in Shroom3+/Gt mice (*p<0.05, ***p<0.001, ****p<0.0001, two-way ANOVA with 
Tukey’s post-hoc test). Data expressed as mean ± SEM; n= 7-11 for NS groups and n= 9-
16 for HS groups.   
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deficient mice, kidneys were assessed by histology directly following the end of the 
dietary treatment period. Staining of kidneys with H&E revealed no overt signs of kidney 
damage in high-salt treated Shroom3+/Gt mice compared to high-salt treated WT mice, 
including no glomerulosclerosis, glomerular cysts, tubular atrophy, or increased 
glomerular size (Figure 3.10). Additional staining with Masson’s Trichrome for 
assessment of tissue fibrosis also revealed no differences in the level of fibrotic injury 
between Shroom3+/Gt mice and WT mice on a HS diet (Figure 3.10). No gross markers of 
kidney damage were seen across any experimental groups. Kidneys were further blindly 
examined by a renal pathologist (Dr. Aaron Haig, University Hospital, London, ON) who 
confirmed the absence of kidney damage.  
3.3 Effects of Shroom3 loss under prolonged exposure to 
high dietary salt intake 
3.3.1 Blood Pressure  
While the HS diet was not expected to promote kidney damage in WT mice, the absence 
of renal damage seen in Shroom3+/Gt mice was surprising as these mice have been 
previously shown to exhibit glomerulosclerosis at one year of age (Khalili et al., 2016). 
However, the mice in this study were younger than one year at the start of the 
experimental period (5-7 months), therefore I sought to determine whether extending the 
salt loading period from 4 weeks to 14 weeks would produce a kidney phenotype. At the 
time of my decision to extend the dietary period to 14 weeks, my second independent 
experiment was just nearing the end of cessation, thus these mice were kept on the diet 
for an additional 10 weeks. However, my n-value for Shroom3+/Gt mice on a NS diet was 
insufficient to allow for statistical comparison (n=2) with Shroom3+/Gt mice on a HS diet. 
Thus, statistical analyses for my long-term study was carried out between Shroom3+/Gt 
mice on a HS diet and WT mice on a NS and HS diet.  
Continuation of the HS diet led to a further reduction in SBP in Shroom3+/Gt mice, with 
significant differences in SBP seen between Shroom3+/Gt mice and WT on a HS diet at 
week 8 (p=0.0168; Figure 3.11D,E) at week 8 and with WT NS mice at weeks 7 and 8  
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Figure 3.10 Histological assessment of kidneys from WT and Shroom3+/Gt mice on a 
short-term high-salt diet. Representative images of kidney sections stained with H&E 
(top panel) and Masson’s Trichrome (bottom panel). Kidneys were extracted from mice 
after the cessation of the four-week dietary period and examined for markers of kidney 
damage. No signs of kidney damage were seen in any of the experimental groups. Black 
arrows in top panel indicate glomeruli that appear to be healthy; no dilation of Bowman’s 
capsule (associated with cystic glomeruli), enlarged glomerular area, or scarring was 
observed. Staining with Masson’s Trichrome revealed no increase in collagen deposition, 
which would be indicated by blue colouring. Findings were confirmed by a renal 
pathologist who did not observe any signs of injury in the experimental groups. n= 2-4 
for NS groups and n= 4-6 for HS groups. Black scale bars = 100 μm.  
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Figure 3.11 Effects of a long-term high-salt diet and Shroom3 loss on systolic blood 
pressure. Time-course of SBP from baseline (week 0) to the end of the prolonged 
treatment period (week 14) for WT (A) and Shroom3+/Gt (B) mice on a NS and HS diet, 
as well as a time-course of SBP of WT and Shroom3+/Gt mice on a NS (C) and HS (D) 
diet. Measurements were taken at weekly time points after the continuation of the dietary 
period using the tail-cuff blood pressure system. A summary of all four groups is shown 
in (E). SBP was significantly lower in Shroom3+/Gt mice on a HS diet compared to WT 
mice on the same diet and WT mice on a NS diet at week 8 (*p=0.0168 vs. WT-HS, 
^^p=0.0023 vs. WT-NS) and compared to WT mice on a NS diet at week 7 (^p=0.0167); 
statistical analysis between groups was conducted using one-way ANOVA with Tukey’s 
post-hoc test. Statistical comparisons to Shroom3+/Gt mice on a NS diet could not be 
conducted due to low n-value (n=2). Data expressed as mean ± SD; n= 4 for WT-NS and 
n=4-6 for HS groups.  
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(week 7 p=0.0167, week 8 p=0.0023; Figure 3.11E). However, those differences were not 
maintained in later weeks. Furthermore, blood pressure variability remained significantly 
higher in Shroom3+/Gt mice compared to WT mice upon prolonged exposure to increased 
dietary sodium intake (p=0.0155 vs. WT HS, p=0.0098 vs. WT NS; Figure 3.12). 
3.3.2 Urinalysis  
To assess kidney function in mice on a long-term HS diet, random spot urine was 
collected from mice and analyzed for urinary protein and creatinine levels at 14 weeks 
from the start of the treatment period. No significant difference in urinary protein to 
creatinine ratio (UPCR) was found between Shroom3+/Gt mice on a HS diet and WT mice 
on a HS and NS diet (Figure 3.13A). Shroom3+/Gt mice on a NS diet exhibited the highest 
UPCR, although the n-value did not allow for analysis of statistical significance. When 
looking at independent values for total urinary protein and creatinine levels, a HS diet 
resulted in significantly decreased urinary creatinine and protein levels in both WT 
(creatinine p=0.0001, protein p=0.0001) and Shroom3+/Gt mice compared to WT mice on 
a NS diet (creatinine p=0.0001, protein p=0.0001; Figure 3.13B,C). Concomitant with 
these results, I noted that a HS diet caused more frequent urination and consequently 
increased water intake in both WT and Shroom3+/Gt mice. This was evidenced by extreme 
dampening of cage bedding that needed to be changed almost daily as well as frequent 
replenishment of drinking water. These observations might also explain the decrease in 
blood pressure observed in some HS mice as increased urine production would be 
accompanied by a decrease in fluid volume and thus blood pressure. In addition, although 
statistical comparisons could not be made, Shroom3+/Gt mice on a NS diet exhibited the 
highest UPCR and total urinary protein levels, which is consistent with previous studies 
that showed loss of Shroom3 caused increased proteinuria in mice at one year of age 
(Khalili et al., 2016). Taken together, these findings suggest that a HS diet decreases 
urinary protein and creatinine levels, that is likely an outcome of the increased water 
intake and urinary output due to salt loading.  
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Figure 3.12 Loss of Shroom3 leads to sustained increases in blood pressure 
variability on a prolonged high-salt diet. The SD of the average SBP value calculated 
from measurements taken weekly throughout the 14-week period of the dietary treatment 
was calculated. When placed on a long-term HS diet, Shroom3+/Gt mice exhibit a 
sustained elevation in pressure variability compared to WT mice on the same diet and 
WT mice on a NS diet (*p=0.0155 vs. WT-HS, ***p=0.004 vs. WT-NS, one-way 
ANOVA with Tukey’s post-hoc test). Statistical comparisons to Shroom3+/Gt mice on a 
NS diet could not be conducted due to low n-value (n=2). Data expressed as mean ± SD; 
n= 4 for WT-NS and n=4-6 for HS groups.  
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Figure 3.13 A high-salt diet decreases urinary protein and creatinine. Random spot 
urine was collected from WT and Shroom3+/Gt mice on a NS diet and HS diet for 
urinalysis to measure the levels of urinary protein/creatinine ratio (A), creatinine (B), and 
protein (C). A high-salt diet causes a significant reduction in the level of urinary protein 
and creatinine in both WT and Shroom3+/Gt mice compared to WT mice on a NS diet 
(****p=0.0001, one-way ANOVA with Dunnett’s multiple comparisons test). Statistical 
comparisons to Shroom3+/Gt mice on a NS diet could not be conducted due to low n-value 
(n=2). One outlier was removed from the WT-NS group as the value was triple that of the 
others in the group. Data expressed as mean ± SD; n= 3 for WT-NS and n=4-6 for HS 
groups.  
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3.3.3 Loss of Shroom3 promotes cardiac hypertrophy on a long-
term high-salt diet  
Long-term BPV sustained past a period of 4 weeks induces cardiac hypertrophy in rats 
that have undergone sinoaortic denervation, a surgical procedure that consists of 
sectioning the baroreceptors within the aortic nerve, thereby inducing cardiac and 
pulmonary remodeling; the procedure is used to model blood pressure variability 
(Guyenet, 2006). In the present study, a long-term high-salt diet was found to cause 
increased heart weight to body weight ratios in Shroom3+/Gt mice compared to WT mice 
on a long-term normal-salt diet (p=0.0111; Fig 3.14), suggesting that loss of Shroom3 
may promote cardiac remodeling resulting in cardiac hypertrophy.  
3.3.4 Evaluation of renal injury  
In order to determine whether prolonged exposure to increased dietary sodium could 
promote renal damage in Shroom3+/Gt mice, kidneys were again subject to histological 
analysis. Assessment of kidneys by H&E staining revealed no overt signs of kidney 
disease across experimental groups, similar to the findings of the short-term HS diet 
(Figure 3.14). H&E slides were blindly examined by the same pathologist (Dr. Aaron 
Haig, University Hospital, London, ON) who also did not see any gross signs of kidney 
injury. Staining with Masson’s Trichrome for fibrotic injury, however, did suggest an 
increase in fibrosis in Shroom3+/Gt mice on a HS diet. Specifically, I observed an increase 
in collagen deposition in the tubular interstitium of Shroom3+/Gt mice on a HS diet 
(Figure 3.15). However, the absence of glomerular injury assessed by H&E staining 
might suggest that the increase in collagen deposition in the tubular interstitium may be 
in its early stages and has not yet pervaded the glomeruli. These results suggest that loss 
of Shroom3 does not increase susceptibility to kidney damage during short-term exposure 
to a high-salt diet, but may potentially increase susceptibility to kidney damage, 
specifically fibrotic injury, during long-term exposure to a high-salt. However, additional 
experiments are needed in order to quantify the potential increase in tubulointerstitial 
fibrosis.  
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Figure 3.14 Loss of Shroom3 increases heart weight to body weight ratio on a long-
term high-salt diet. The ratio of heart weight to body weight in wild-type and 
Shroom3+/Gt mice fed either a normal-salt or high-salt diet over a long-term 14-week 
period. When placed on a long-term HS diet, Shroom3+/Gt mice display a higher heart to 
body weight ratio, indicative of cardiac hypertrophy, compared to WT mice on a NS diet 
(*p=0.0111, one-way ANOVA with Tukey’s post-hoc test). Statistical comparisons to 
Shroom3+/Gt mice on a NS diet could not be conducted due to low n-value (n=2). Data 
expressed as mean ± SEM; n= 4 for WT-NS and n=4-6 for HS groups.  
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Figure 3.15 Histological assessment of kidneys from WT and Shroom3+/Gt mice on a 
long-term high-salt diet. Representative images of kidney sections stained with H&E 
(top panel) and Masson’s Trichrome (bottom panel). Kidneys were extracted from mice 
after the cessation of the 14-week dietary period and examined for markers of kidney 
damage. Staining with H&E revealed no gross pathological markers of glomerular injury 
in Shroom3+/Gt mice (black arrow). Staining with Masson’s Trichrome revealed an 
increase in collagen deposition in Shroom3+/Gt mice, with an increased deposition in the 
HS group. Arrowhead indicates the presence of fibrotic tissue in the tubular interstitium 
as seen by the area in blue. N=4 (WT-NS), n=2 (Shroom3+/Gt-NS), n=6 (WT-HS), n=4 
(Shroom3+/Gt -HS). Black scale bars = 100 μm.  
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3.4 Functional assessment of human SHROOM3 variants   
The in vitro aspect of this thesis focussed on analyzing if there are functional deficits in 
the ability of known SHROOM3 variants identified by the NHLBI to cause apical 
constriction. As described in 1.4.1, previous studies have suggested that human 
SHROOM3 variants within the population may have functional consequences. Out of the 
hundreds of SHROOM3 variants identified by the NHLBI, several were predicted to be 
probably damaging based on PolyPhen-2 analysis. From this dataset of SHROOM3 
variants predicted to be probably damaging, our lab previously compiled a list of variants 
of interest based on the following criteria: they occur in the coding region of SHROOM3 
and they have been identified more than 5 times in the alleles sequenced to date (see 
Appendix D); four variants have substitutions in one of Shroom3’s known domain 
locations. Whether these variants exhibit impaired function remains unknown, although 
two of them have already been associated with heterotaxy (Tariq et al., 2011). Thus, to 
assess the functional consequences of these variants, I used an established assay to test 
for the ability of Shroom3 to drive apical constriction in transfected MDCK epithelial 
cells. The variants were generated using a bicistronic vector that also expresses GFP, for 
3 of the 4 variants that occur in a known domain location, and subsequently examined 
their ability to drive apical constriction was tested. Prior to transfection, all of the 
expression vectors were verified by sequencing to confirm that the expected mutation 
substitution occurred (see Appendix E). 
Transfection of MDCK cells with each of the three SHROOM3 variants resulted in 
markedly reduced apical constriction compared to cells transfected with WT SHROOM3, 
with apical surface areas comparable to those of control cells transfected with GFP alone 
(Figure 3.15A). To quantify the degree of apical constriction, the apical surface defined 
by ZO-1 was traced and measured for transfected cells as well as neighboring 
untransfected cells (see Appendix F). As expected, the apical surface area of cells 
transfected with WT SHROOM3 was significantly decreased compared to the apical 
surface area of neighboring untransfected cells (p<0.0001; Figure 3.15C). The apical 
surface area of MDCK cells transfected with the SHROOM3 variants G60V, T1012N, 
and G1864D was not significantly reduced compared to untransfected neighboring cells,  
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indicating that these variants have reduced ability to drive apical constriction. 
Interestingly, the apical surface area of MDCK cells transfected with the GFP control or 
the G1864D SHROOM3 variant was found to be significantly larger than neighboring, 
untransfected cells, perhaps due to the nature of the transfection itself. Moreover, the 
apical surface area of cells expressing WT SHROOM3 was significantly smaller than 
cells transfected with G60V (p=0.003), T1012N (p=0.0001), or 1864D (p=0.0001), 
indicating that the SHROOM3 variants have abrogated apical constriction ability (Figure 
3.16B). There was no significant difference in the apical surface area of cells transfected 
with a variant compared to those transfected with GFP alone (G60V p=0.0621, T1012N 
p=0.4941, G1864D p=0.9026). These results suggest that three of the SHROOM3 variants 
identified by the NHLBI with substitutions in known domain locations and that are 
predicted to be damaging have impaired cellular function with respect to their ability to 
drive apical constriction.        
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Figure 3.16 Human variants of SHROOM3 have attenuated ability to drive apical 
constriction. Representative fluorescence images of ZO-1 (red) and GFP (green) labelled 
MDCK cells transfected with either an empty GFP plasmid (top panel), WT SHROOM3 
(second panel), or the indicated plasmids carrying one of the SHROOM3 variants (bottom 
three panels) (A). Transfected cells were visualized by GFP (left panel), apical cell-cell 
boundaries were visualized by staining with ZO-1 antibody (middle panels), and nuclei of 
cells were marked with DAPI (right panel). MDCK cells transfected with a GFP plasmid 
alone display no decrease in cellular area (white arrowhead), while cells transfected with 
WT SHROOM3 display a marked decrease in cellular area, indicating apical constriction 
(white arrow). Transfection of MDCK cells with the SHROOM3 variants resulted in cells 
of similar size to those transfected with GFP alone and of greater size compared to those 
transfected with WT SHROOM3, indicating reduced apical constriction ability. To 
quantify apical constriction, the apical area of transfected cells outlined by ZO-1 was 
traced and measured using ImageJ. Differences in apical constriction ability between 
groups was analyzed by comparing the apical area of transfected cells (B) and comparing 
transfected cells with neighboring untransfected cells within groups (C). All three of the 
SHROOM3 variants analyzed had significantly increased apical area compared to WT 
SHROOM3 (****p=0.0001, one-way ANOVA with Tukey’s post-hoc test) and were not 
found with decreased apical areas in comparison to untransfected neighboring cells 
(unpaired t-test).  White scale bar = 50 µm, n=23-25 cells analyzed from at least three 
independent experiments.  
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Chapter 4  
4 Discussion 
4.1 Overview 
The interplay between genetics and the environment is central to the development of 
complex human diseases. Recent studies, including previous work conducted in our lab, 
have demonstrated an important role for Shroom3 in both the developing and mature 
kidney, lending functional support for the GWAS that have strongly associated 
SHROOM3 with CKD (Khalili et al., 2016; Yeo et al., 2015). At the same time, the 
emergence of evidence linking human variants of SHROOM3 to disorders including 
heterotaxy and diseases of the nervous system have necessitated the need to further 
explore and characterize the functional changes associated with these potentially 
damaging variants (Ganief et al., 2017; Tariq et al., 2011). In this thesis, I sought to 
investigate the potential consequences of alterations in the expression and sequence of 
SHROOM3 using an in vivo and in vitro model, respectively. Here, I demonstrate that 
loss of Shroom3 may increase the salt sensitivity of blood pressure and that rare human 
variants of SHROOM3 have abrogated cellular function.  
4.2 Loss of Shroom3 elevates blood pressure variability but 
not hypertension in the presence of a sodium insult  
Our lab has previously shown that loss of Shroom3 during development leads to 
glomerular defects in mice attributed to reduced glomerular number and podocyte foot 
process effacement that are manifested by adult onset proteinuria and glomerulosclerosis 
(Khalili et al., 2016). As described in Chapter 1, the kidney plays an essential role in the 
regulation of blood pressure and impaired renal sodium excretion leads to an increase in 
systemic blood pressure. Previous studies have shown that under high dietary salt 
conditions, knockdown or knockout of genes implicated in kidney function are associated 
with the development of hypertension and concomitant renal injury (Daumerie et al., 
2010; Schlote et al., 2013; Ye et al., 2006). Conversely, in the present study, a high-salt 
diet was not found to cause hypertension in Shroom3 deficient mice (Figure 3.6). 
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However, loss of Shroom3 was associated with greater fluctuations in blood pressure 
under high-salt conditions (Figure 3.7). This was evidenced by both a greater change in 
systolic blood pressure throughout the dietary period when compared to baseline, with 
both positive and negative changes taken into the same consideration, as well as 
significantly elevated blood pressure variability in Shroom3+/Gt mice on a HS diet (Figure 
3.8 & 3.9).  
Both long-term and short-term blood pressure variability are quickly emerging as 
important risk factors for cardiovascular disease and all-cause mortality, independent of 
mean blood pressure (Dolan & O’Brien, 2010; Mancia, 2012; Parati et al., 2013; 
Rothwell et al., 2010; Stevens et al., 2016; Suchy-Dicey et al., 2013). Traditional 
approaches for quantifying short-term 24 hour BPV in mice have involved power spectral 
analysis of SBP using surgically implanted telemetry devices (Desjardins et al., 2008; 
Farah et al., 2004; Stauss et al., 1999). However, as this procedure was outside the scope 
of this thesis, the standard deviation of SBP was used as an index for BPV. The SD of 
SBP is an established index for BPV in humans. Here, I found that a HS diet generally 
caused a greater variability in SBP, and this variability was significantly exacerbated by 
loss of Shroom3. The increased BPV observed in WT mice on a HS diet is consistent 
with a previous study that showed a HS diet elevated BPV in normotensive, salt-resistant 
rats through the sodium-induced enhancement of sympathetic nerve activity, without 
increasing the mean BP (Simmonds et al., 2014). Importantly, the increased BPV seen in 
Shroom3+/Gt mice suggests that loss of Shroom3 attenuates the ability of blood pressure to 
autoregulate when challenged with increased dietary sodium.  
The observation that a high-salt diet does not cause hypertension in Shroom3+/Gt mice are 
complemented by our histological analyses, which revealed that Shroom3+/Gt mice on a 
HS diet do not exhibit any hallmarks of kidney damage, including glomerular and fibrotic 
injury, in comparison to WT controls on a NS diet (Figure 3.10). Sustained elevations in 
systemic blood pressure propagate kidney damage by increasing glomerular capillary 
pressure, which induces glomerular hypertrophy and consequent podocyte foot process 
effacement, eventually culminating into glomerulosclerosis (Endlich & Endlich, 2012; 
Kretzler et al., 1994). As podocyte morphology was not examined in this thesis, it cannot 
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be excluded that a HS diet did not induce podocyte injury in Shroom3+/Gt mice. However, 
the lack of overt glomerular injury observed in these mice would suggest that if the HS 
diet did induce such podocyte injury, it had not progressed to a stage capable of 
transmitting the injury at the level of the glomerulus.  
The renin-angiotensin system (RAS) and the type I angiotensin receptor (AT1) have been 
established as key contributors in the development of essential hypertension, primarily 
through their actions in the kidney (Crowley et al., 2006). Aberrant activation of the RAS 
has been directly linked to hypertension and cardiovascular morbidity through the 
stimulation of angiotensin II (Ang II) activity, with KO of AT1 receptors in the kidney 
being sufficient to ameliorate Ang II-dependent hypertension (Crowley et al., 2006; Lonn 
et al., 1994). This provides the basis for the administration of angiotensin-converting-
enzymes (ACEs) and angiotensin receptor blockers for the reduction of blood pressure in 
patients with hypertension and kidney disease (NHLBI, 2004). Importantly, a unifying 
common pathway for the onset of salt-sensitive hypertension seems to implicate a critical 
role for Ang II activity in the kidney, as high intrarenal Ang II levels contribute to 
increased sodium and water retention (Kobori et al., 2007). This is directly evidenced by 
the Dahl salt-sensitive (DS) rat model, in which a high-salt diet augments intrarenal 
angiotensinogen levels in DS rats and contributes to impaired renal sodium excretion and 
consequent systemic hypertension (Kobori et al., 2003). This also explains why numerous 
past studies that have used a high-salt model for hypertension have coupled the high-salt 
diet with simultaneous administration of Ang II in order to induce hypertension in non 
salt-sensitive animals (Chen et al., 2010; Crowley et al., 2011; Lee et al., 2012; Manhiani 
et al., 2015; Singh et al., 2009; Wang et al., 2015). In many of these studies, a high-salt 
diet alone was either not sufficient to induce hypertension in the absence of Ang II 
infusion or salt-dependent hypertension was exacerbated upon Ang II administration (Lee 
et al., 2006; Manhiani et al., 2015; Singh et al., 2009). Therefore, while a high-salt diet 
was not sufficient to induce hypertension in Shroom3+/Gt, it may be the case that salt-
sensitive hypertension in Shroom3+/Gt mice critically depends on activation of the RAS in 
the kidney. Thus, an evident focus of future studies should be on determining whether 
Shroom3+/Gt mice develop salt-sensitive hypertension upon Ang II infusion. Although an 
alternative possibility would appear to be that hypertension in Shroom3+/Gt mice is simply 
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not salt-sensitive, the increased blood pressure variability in Shroom3+/Gt mice brought on 
by a high-salt diet would suggest that their blood pressure response is in fact salt-
sensitive.  
In keeping with the importance of using a model that includes Ang II administration, a 
study on DSS rats found that treatment with a HS diet for four weeks led to significant 
hypertension, proteinuria, glomerulosclerosis, and tubulointerstitial fibrosis (Rafiq et al., 
2014). Subsequent administration of hydralazine (HYD), which mimics the effects of 
dietary sodium restriction, was found to ameliorate hypertension but not renal 
histopathologies. However, treatment with HYD in combination with Angiotensin II typ 
1 receptor blocker and a calcium channel blocker that is known to enhance the protective 
effects of ARBs was found to elicit strong renoprotective effects that regressed renal 
injuries induced by a HS diet (Rafiq et al., 2014). This suggests that fibrotic damage 
caused by salt-sensitive hypertension critically depends on the activity of Ang II as 
dietary salt restriction by itself was not sufficient to reverse renal injury. Thus, Ang-II 
infusion may not only be valuable for studying salt-sensitive hypertension, but also for 
assessing salt-sensitive kidney damage.         
4.3 Potential long-term effects of Shroom3 loss upon 
prolonged exposure to a high-salt diet   
Age is another established risk factor for both the development of hypertension as well as 
CKD (National Kidney Foundation, 2002; NHLBI, 2004). In particular, CKD is a disease 
of the elderly rather than the young as kidney function progressively declines with age 
(Levey & Coresh, 2012). The previous finding in our lab that loss of Shroom3 leads to 
glomerulosclerosis and proteinuria in adult mice was dependent on age. Specifically, 
these functional consequences were not observed in mice at 3 months of age, but rather at 
one year of age (Khalili et al., 2016). The absence of both hypertension and renal injury 
in the Shroom3+/Gt mice used in my study may be an outcome of their younger age, as 
they were between the ages of 5-7 months at the start of the experimental period. 
Additionally, previous studies that have used a high-salt diet model for hypertension 
maintained animals on the diet for extended periods upwards of four weeks (Bertorello et 
al., 2015; Laverman et al., 2003; R. E. Schmieder et al., 1988; Vasdev et al., 2006). 
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Extending the period of dietary salt-loading has been shown to exacerbate hypertension, 
proteinuria, and renal injury in DS rats (Rafiq et al., 2014). Additionally, in Sprague-
Dawley rats, a long-term HS diet of 8 weeks was found to result in hypertension, 
proteinuria, and renal injury, while a short-term 4 week HS diet had no such 
consequences (Gu et al., 2008). While the effects of a long-term HS diet have been well-
established in rat models, less is known about the effects of extended salt loading in mice 
(Van Vliet & Montani, 2008). In the present study, extending the salt loading period to 14 
weeks did not induce hypertension in Shroom3+/Gt mice (Figure 3.11). However, a 
significant finding was that BPV was maintained throughout the prolonged dietary period 
(Figure 3.12).  
A critical outcome of increased long-term BPV is increased end organ damage (Höcht, 
2013). Assessment of heart and body weight of mice in my current study demonstrated 
that loss of Shroom3 is associated with cardiac hypertrophy under long-term high-salt 
conditions (Figure 3.14). Blood pressure variability can be experimentally induced 
without sustained hypertension through sinoaortic denervation (SAD) (Miao et al., 2003). 
In sinoaortic denervated rats, a chronic increase in BPV results in myocardial damage (Su 
& Miao, 2001). At 16 weeks post-surgical denervation, cardiomyocyte swelling was 
observed and at 32 weeks post-surgical denervation, SAD rats were found with interstitial 
fibrosis in the myocardium (Su & Miao, 2001). SAD rats also have overt symptoms of 
kidney damage, with thickening of the Bowman’s capsule being visible 8 weeks, 
interstitial fibrosis visible at 16 weeks, and severe glomerular lesions and glomerular 
collapse visible at 32 weeks post-surgical denervation (Su & Miao, 2001). Importantly, 
the organ damage observed in SAD rats was directly caused by a high BPV, independent 
of high BP; chronic SAD in rats causes a significant increase in BPV but no change in the 
24-hour BP average. Therefore, BPV is a risk factor for organ damage independent of the 
presence of hypertension (Su & Miao, 2001). Moreover, in rat models, a high-salt diet 
(8%) induces cardiac hypertrophy through a blood pressure-independent mechanism 
(Ferreira et al., 2010; Radin et al., 2008). This suggests that the cardiac hypertrophy 
observed in Shroom3+/Gt mice on a long-term HS diet may be a myocardial outcome of 
their sustained elevation in long-term BPV.  
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A potential link between Shroom3 and cardiac function is strengthened by previous work 
in our lab that has revealed that Shroom3 is expressed throughout the myocardium during 
cardiogenesis and that loss of Shroom3 results in cardiac defects in embryonic mice. 
Furthermore, another significant finding in the present study was the observation that 
DBP in Shroom3+/Gt mice was significantly reduced on a short-term HS diet. This 
decrease was not seen in WT mice on a HS diet or Shroom3+/Gt mice on a NS diet, 
indicating that the reduction in DBP in HS-Shroom3+/Gt mice was dependent on loss of 
Shroom3 in the presence of increased dietary sodium intake (Figure 3.4). Recently, a 
large observational study conducted on the Atherosclerosis Risk In Communities cohort 
found that a low DBP was strongly associated with myocardial damage and coronary 
heart disease (McEvoy et al., 2016). Similarly, a separate study has also strongly 
associated isolated diastolic hypotension with incident heart failure in older adults 
(Guichard et al., 2011). Therefore, the changes in blood pressure observed in response to 
a HS diet in Shroom3+/Gt mice could be due to an underlying cardiac phenotype rather 
than one associated with the kidney.     
Examination of the functional effects of Shroom3 loss on the kidney under long-term 
high-salt conditions revealed that HS Shroom3+/Gt mice displayed significantly lower 
urinary protein and creatinine levels, corresponding to a decrease, although not 
significant, in the urinary protein to creatinine ratio, compared to WT mice on a NS diet 
and WT mice on a HS diet (Figure 3.13). A UPCR is used as an index for proteinuria for 
random spot urine samples. However, I wanted to separately examine the total urinary 
protein and creatinine levels because I noticed that a HS diet was causing increased water 
intake and more frequent urination in both WT and Shroom3+/Gt mice. Although these 
two variables were not directly measured, it is clear that they had an impact on urine 
composition. Low urinary creatinine levels are an indication of an abnormally large 
consumption of water, thus in the case of mice on a HS diet, a urinalysis may not be an 
accurate method for assessment of proteinuria. It can therefore not be excluded that 
Shroom3+/Gt mice on a HS diet do not exhibit proteinuria. However, given that 
proteinuria is an early clinical manifestation of high blood pressure, owing to the leakage 
of protein into urine due to foot process effacement caused by increased pressure load to 
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the renal microvasculature, and that Shroom3+/Gt mice were not found to be hypertensive, 
it is most likely the case that these mice were also not proteinuric.  
Glomerular hyperfiltration is a phenomenon that occurs in both hypertensive nephropathy 
as well as diabetic nephropathy, and is proposed to be a pathogenic mechanism of renal 
injury common to both diseases. It is characterized by the compensatory rise in single-
neprhon GFR in response to some form of renal insult. As discussed in Chapter 1, 
Brenner’s hypothesis proposed that this renal insult could be in the form of reduced 
nephron endowment, inducing hyperfiltration in the remaining glomeruli and ultimately 
culminating into systemic hypertension and glomerulosclerosis. Importantly, glomerular 
hyperfiltration has been shown to precede the development of microalbuminuria and thus 
macroalbuminuria and proteinuria in both stage 1 hypertensive patients as well as type I 
diabetic patients (Magee et al., 2009; Palatini et al., 2006). Moreover, glomerular 
hyperfiltration in humans occurs in the earliest stages of hypertension, and is driven by 
the interactions between Ang II and the sympathetic nervous system in response to a 
stressor, which can then propagate into persistent hypertension (Schmieder et al., 1997).  
Although in the present study I did not observe hypertension in Shroom3+/Gt mice placed 
on a long-term HS diet, it cannot be excluded that the Shroom3+/Gt mice were in the 
earliest stages of hypertension where elevations in blood pressure were not sustained long 
enough to be detected nor can it be excluded that Shroom3+/Gt mice may be more 
susceptible to hypertension in the presence of an additional stressor such as older age or 
augmented Ang II levels. Therefore, I propose that future experiments should focus on 
measuring eGFR, through assessment of serum creatinine levels, rather than proteinuria, 
in order to determine whether Shroom3+/Gt mice on a HS diet exhibit increased eGFR, 
which would be indicative of a hyperfiltration state. If an abnormally high eGFR is 
observed in Shroom3+/Gt mice on a HS diet, it would provide evidence that these mice 
may be in the early stages of hypertension. Although glomerular hyperfiltration is also a 
mechanism present in the early stages of diabetes, increased salt intake in early type I 
diabetes, unlike salt-dependent hypertension, actually leads to a decrease in eGFR, a 
phenomenon known as the “salt paradox” (Vallon, 2003). Thus, an abnormally high 
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eGFR in the presence of increased dietary sodium intake, would most likely point 
towards the direction of hypertensive rather than diabetic nephropathy.  
Alternatively, it is possible that loss of Shroom3 involves a combination of the 
pathogenic mechanisms associated with both diabetic nephropathy and hypertension. As 
mentioned in 1.2.6, a 2012 GWAS conducted by Köttgen et al. revealed that the 
association between SHROOM3 and lower eGFR also corresponded to lower 
albuminuria. This association was abnormal in comparison to the traditional inverse 
relationship between eGFR and proteinuria. The authors postulated that this atypical 
relationship may have two potential explanations: Shroom3 may either be exerting 
pleiotropic effects or is interacting with mechanisms that substantiate both a higher eGFR 
and a higher urinary albumin to creatinine ratio, as in the case of glomerular 
hyperfiltration states present in early diabetes and hypertension. Furthermore, a 
subsequent GWAS found a strong association between SHROOM3 and eGFR in type 2 
diabetes, and this association was dependent on the presence of albuminuria (Deshmukh 
et al., 2013). These findings suggest that the presence of a hyperfiltration state in 
Shroom3+/Gt mice on a HS diet is highly likely and further necessitates the need for future 
experiments to assess eGFR.     
Similar to the findings from my short-term HS study, histological analyses revealed that a 
long-term HS diet of 14 weeks did not induce glomerular injury in Shroom3 deficient 
mice (Figure 3.15). However, Shroom3+/Gt mice appear to display slightly increased 
collagen deposition in the interstititium, although my observation was not confirmed by a 
pathologist. CKD is defined as a progressive disease and overt histopathological as well 
as functional changes are often not observable in the early stages of CKD (Rysz et al., 
2017). The use of biomarkers in the early detection of CKD has thus become an 
increasingly important area of focus in CKD diagnostic research (Khan & Pandey, 2014; 
Rysz et al., 2017). Future experiments should be aimed at determining whether 
Shroom3+/Gt mice on a HS diet displayed altered expression of genes implicated in the 
molecular mechanisms involved in kidney injury using established biomarkers. These 
biomarkers would be more sensitive to the early detection of CKD, present before CKD 
is manifested by histopathological and functional changes.  
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Taken together, my in vivo studies have elucidated the potential effects of Shroom3 loss 
on blood pressure and the kidney under acute and chronic exposure to increased dietary 
sodium. Additionally, I suggest a novel approach to studying salt-dependent hypertension 
in Shroom3+/Gt mice that involves augmentation of the renin-angiotensin system as an 
additional stressor. While salt-sensitive hypertension has been extensively used in rat 
models, its use in mice is still a relatively emerging field. As alluded to throughout this 
Discussion, the most apparent limitation present in my in vivo work was the 
establishment of a hypertensive model using a high-salt diet. As C57BL/6 mice are 
normally not salt-sensitive, the addition of a secondary insult other than salt may be 
necessary to induce hypertension in these animals. Furthermore, future experiments 
examining blood pressure variability in Shroom3+/Gt mice should use the implantable 
blood pressure radiotelemetry system for BPV analysis that employs power spectral 
analysis rather than the tail-cuff system. Due to the tail-cuff system being non-invasive, it 
requires physical restraint of the animal, and stress-induced blood pressure changes are 
an inevitable limitation to this method. Although the radiotelemetry method is much 
more costly and invasive, it would eliminate the unavoidable physiological blood 
pressure response to stress. Radiotelemetry also allows for continuous 24-hour blood 
pressure monitoring of conscious animals in their natural environment, providing a more 
sensitive arterial pressure reading compared to the single-point periodic monitoring of 
blood pressure by the tail-cuff system (Zhao et al., 2011).  
In addition, an important caveat with respect to the present study is that BPV was 
analyzed within the given experimental groups (or populations) rather than at the 
individual level. Further assessment would be needed to determine if the BPV of the 
population reflects the outcomes of increased individual BPV. Lastly, one study assessing 
the validity of the tail-cuff blood pressure system showed that the tail-cuff method may 
underestimate DBP, therefore the findings in my study that demonstrated loss of 
Shroom3 may result in decreased DBP under high-salt conditions would have to be 
confirmed using other blood-pressure measurement systems (Feng et al., 2008).    
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4.4 Altered cellular function of human SHROOM3 variants  
Several human variants of SHROOM3 that exist within the current population have been 
identified by the NHLBI and have been predicted to be probably damaging by PolyPhen-
2 analysis. Two of these identified SHROOM3 variants have already been found to be 
linked to heterotaxy in a separate study (Tariq et al., 2011). Here, I provide the first direct 
evidence that at least three of the SHROOM3 variants identified by the NHLBI, two of 
which are the variants that been linked to heterotaxy in the aforementioned study, have 
abrogated cellular function. Using an established in vitro assay for Shroom3 function in 
MDCK epithelial cells, I demonstrated that cells transfected with any of the three 
SHROOM3 variants have significantly reduced ability to undergo apical constriction, as 
evidenced by the increased apical area in cells transfected with a SHROOM3 variant in 
comparison to cells transfected with wild-type SHROOM3.  
While previous studies have linked human variants of SHROOM3 to complex diseases, 
no studies to date have provided mechanistic evidence that these variants have functional 
consequences. Importantly, the observation that the two human SHROOM3 variants 
associated with heterotaxy in humans have attenuated apical constriction activity 
provides the first functional link between these variants and the PolyPhen2 prediction that 
these variants are damaging. A clear aim for future studies would then be to characterize 
the molecular mechanisms underlying this loss of function observed in the SHROOM3 
variants. Given that the three SHROOM3 variants here that have been shown to have 
compromised cellular function have mutations in one of Shroom3’s known domain 
locations, it would be of priority to analyze the interactions between Shroom3 and 
ROCK1/2 as well as Shroom3 and actin. In particular, ROCK has been found to be 
required for proper left-right patterning in humans, and it is the absence of proper left-
right patterning that causes the disease phenotype in heterotaxy patients (Fakhro et al., 
2011; G. Wang et al., 2011). One of the SHROOM3 variants associated with heterotaxy 
that was assessed in the present study, G1864D, contains the substitution in the ASD2 
domain, which is the domain that directly binds to ROCK. This strongly suggests that the 
abrogated apical constriction function of this variant is likely due to a perturbation in 
Shroom3’s interaction with ROCK.   
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4.5 Future Directions and Conclusions  
As our current model for Shroom3 loss involves a global knockdown of Shroom3, the 
inability to delineate between the confounding effects of Shroom3 loss in the heart and 
the kidney presents another limitation to our in vivo studies. Currently, our lab has been 
working on generating a conditional knockout of Shroom3 using a Cre-Lox 
recombination model, specific to the kidney. This conditional knockout model would 
circumvent the embryonic lethality associated with complete loss of Shroom3 as it would 
still be expressed in the neural tube during development. Through the use of podocyte-
specific promoters, or other kidney cell type promoters, conditional knockout of Shroom3 
would help further elucidate its kidney-specific role while eliminating the confounding 
effects of global Shroom3 loss. Future studies using this model will be critical in 
establishing a causative relationship between the podocyte defects associated with loss of 
Shroom3 and reduced nephron endowment, as well as differentiating between the 
pathogenic mechanisms of kidney disease and heart disease.    
In summary, the findings presented in this thesis have provided insight into how loss of 
Shroom3 or alterations in the sequence of Shroom3 may confer risk for disease. I have 
conducted the first experiments aimed at determining whether loss of Shroom3 increases 
susceptibility to hypertension, a leading cause and comorbidity of CKD, in the presence 
of a sodium insult. The increase in the consumption of processed foods observed in the 
diets of Western societies has made it even more important to determine whether some 
individuals may be predisposed to the ramifications of increased dietary sodium intake. 
While the present study showed that partial loss of Shroom3 did not induce hypertension 
in mice in the presence of a high-salt diet, loss of Shroom3 was found to be associated 
with greater variability in blood pressure in response to a high-salt diet. The implications 
of these findings are relevant to the pathophysiology of CKD especially when taking into 
consideration the importance of blood pressure control at all CKD stages. If loss of 
Shroom3 augments salt-sensitive blood pressure variability, then individuals that possess 
compromised Shroom3 function may be at higher risk for end-organ damage under 
increased dietary sodium conditions. An important preemptive course of action in these 
individuals would then be reducing salt intake in combination with continuous blood 
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pressure monitoring. However, further work using more definitive inducers of 
hypertension in salt-resistant mice, including the established Ang II infusion model for 
hypertension, will be needed to ascertain the salt-sensitive blood pressure response 
caused by loss of Shroom3. Moreover, overcoming the limitations of the salt-resistant 
nature of C57BL/6 mice will be necessary in order to determine whether a deficiency in 
Shroom3 predisposes individuals to salt-sensitive hypertension.    
Through in vitro analysis, my work provides the first evidence of the functional 
consequences of human SHROOM3 variants that have been predicted to be damaging by 
the NHLBI, and two of which have been previously associated with heterotaxy in 
humans. Exploring the underlying molecular mechanisms of these variants will be an 
important future experiment. Additionally, to determine whether these functional 
consequences directly translate into human disease traits, analysis will have to be 
conducted to characterize the effects of these SHROOM3 variants using in vivo models.   
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Appendices  
Appendix A: Supplemental information for blood pressure measurements and list of 
mice omitted from statistical analysis  
The nature of the tail-cuff system requires that the mouse is conscious and inevitably, 
there were days where blood pressure measurements could not be obtained or had to be 
omitted. In the former case, such instances included when a mouse exhibited resistance 
towards being placed in the holder or displayed frequent movement or signs of stress 
when blood pressure was being measured. Although measurements were re-taken the 
next day with no issues in the majority of instances, there were rare cases where the 
mouse also displayed signs of distress the following day, and thus, no blood pressure 
measurement could be obtained for that mouse during that week. Additionally, after 
blood pressure data was collected on any given day, the mean and standard deviation of 
30 cycles for each individual mouse was calculated. If the standard deviation was greater 
than 30 for any mouse on a given day, the blood pressure data from that day was not 
included in analysis, as recommended by standard protocol.  
The statistical analysis for my physiological time-course data included a two-way 
ANOVA analysis with a Tukey’s post-hoc test for significant differences between 
experimental groups and a repeated-measures one-way ANOVA with a Dunnett’s 
multiple comparison test for significant differences within groups in comparison to 
baseline values. For repeated measures one-way ANOVA, analysis cannot be conducted 
with missing values, and as stated above, there were instances where data could not be 
obtained on two sequential days in a given week. Three individuals in total were omitted 
from repeated-measures one-way ANOVA analysis due to missing values: a WT NS 
mouse that did not provide readings for weeks 2 and 4, a WT HS mouse that did not 
provide a reading for week 4, and a Shroom3+/Gt HS mouse that was euthanized after 
week 1 upon veterinary request due to overt symptoms of severe, spontaneous 
neurological damage. However, because the two-way ANOVA analysis between groups 
is not repeated-measures, the three mice were included in analysis.   
  
126 
 
 
 
Appendix B: Representative variability in SBP response of Shroom3+/Gt mice on a 
high-salt diet. Time-course of SBP plotted for each individual mouse for WT mice on a 
NS diet (A), Shroom3+/Gt mice on a NS diet (B), WT mice on a HS diet (C), and 
Shroom3+/Gt mice on a HS diet (D) over the four-week treatment period. Upon initiation 
of the HS diet, Shroom3+/Gt mice exhibited large variation in their blood pressure 
response, prompting the analysis of absolute change in SBP as well as blood pressure 
variability. Due to some mice exhibiting a large decrease in SBP while others exhibited a 
large increase, the mean SBP of the group was not significantly different from that of WT 
mice on a HS diet. Of note, the WT mouse on a NS diet mentioned in 3.1.1 that gained a 
large amount of weight in the last two weeks of the experimental period and exhibited 
extremely high blood-pressure levels, is indicated in blue in (A). Due to missing values, 
the individual mice described in Appendix A were also omitted from these figures. N=10 
for WT NS, n=7 for  Shroom3+/Gt NS, n=15 for WT HS, n=9 for Shroom3+/Gt HS. 
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Appendix C: SBP measurements used for BPV analysis. Time-course of SBP taken at 
various days throughout the four-week dietary period. In total, 11 measurements were 
taken for each mouse and the individual SD of the 11 SBP measurements was used as an 
index for BPV. N=7-11 for NS groups, n=9-16 for HS groups.  
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Appendix D: List of identified human SHROOM3 variants of interest. Based on the 
criteria described, these variants were previously selected as variants of interest by our 
lab. The present study has analyzed the three variants marked by an asterisk (*).  
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Appendix E: Representative electropherograms of variants confirmed by DNA 
sequencing. Sequencing results indicating successful mutagenesis of variants. Black 
arrows indicate the location of the substitution.  
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Appendix F Representative analysis of apical constriction determined by ZO-1 
staining. Cells were labeled with an antibody against ZO-1 (anti-ZO-1, red) and nuclei 
were labeled with DAPI (blue). Transfected cells were visualized by GFP (green). To 
determine apical area of the transfected cell, the apical cell boundary outlined by ZO-1 
was traced (indicated in yellow). To determine apical area of neighboring cells, the apical 
cell boundary outlined by ZO-1 was traced for non-GFP expressing cells (indicated in 
white). Only cells that were directly in contact with the cell boundary of the transfected 
GFP-expressing cell were considered “neighboring” cells (indicated in numbers). The 
GFP control vector is shown here.   
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